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INTRODUCTION 
Staphylococcus aureus is the most frequently encountered 
pathogen isolated from clinical specimens. Staphylococcus aureus has the 
ability to asymptomatically colonize the normal population either 
persistently or transiently. 30% of humans are likely to be nasal carriers. 
Person to person contact or contact with fomites plays a role in its 
transmission. Loss of normal skin barrier & presence of predisposing 
factors such as diabetes and HIV complicates infection.  
Staphylococcus aureus causes variety of human infections ranging 
from minor skin diseases such as furuncles, cellulitis, abscesses to life 
threatening infections like toxic shock syndrome, staphylococcal scalded 
skin syndrome, endocarditis, pneumonia & septicemia. 
Penicillin was the drug of choice to which Staphylococcus aureus 
developed resistance by producing the enzyme betalactamase. So  
methicillin was introduced in1959. But methicillin resistant 
staphylococcus aureus (MRSA) fastly appeared in hospitals in 19611.  
Prolonged hospitalization, indiscriminate use of antibiotics, and 
indwelling medical devices were the cause for the appearance and spread 
of MRSA. The  nosocomial multidrug resistant  MRSA(HA -MRSA) 
strains have a high effect on patient morbidity and mortality .Community 
associated MRSA(CA-MRSA) strains harbour Panton-Valentine 
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leucocidin gene associated with  fulminant infections, such as necrotizing 
pneumonia . 
Betalactam agents bind to PBP in cellwall of staphylococcus 
aureus resulting in disruption of peptidoglycan synthesis & bacterial cell 
death. The mecA gene coding for PBP2A in cell wall of MRSA 
harboured by mobile SCCmec chromosome is responsible for methicillin 
resistance.   
CA-MRSA possess a small SCCmectype IV, V, or VII, which is 
transferred easily by transduction than the larger SCCmec types I, II, and 
III in HA-MRSA2,7, 52. 
Detection of MRSA can be performed by an oxacillin or cefoxitin 
disc diffusion test. Cefoxitin is a strong inducer of mec A gene and thus 
helps in detection of MRSA.                           
 Alternatively the macrolide- lincosamide streptogramin B group of 
antibiotics can be used for treating MRSA infection. Clindamycin, a 
lincosamide antibiotic has become an attractive option for clinicians 
because of its bioavailability both in oral & intravenous formulations.   
 It has excellent tissue penetration.It is the treatment of option in 
individuals with penicillin allergy and renal impairement. Clindamycin 
has been used to treat pneumonia, soft-tissue and musculoskeletal 
infections due to MRSA .It can be used both in adults and children3. 
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However, fear of appearance of clindamycin resistance during 
therapy has discouraged some clinicians prescribing it.  
The mechanism of inducible clindamycin resistance ( iMLSB )  is 
due to target site modification mediated by erm gene which can be 
expressed by an inducer like erythromycin  or constitutively (cMLSB ). 
The overlapping binding sites of macrolides, lincosamides,and 
streptogramins B in 23S rRNA accounts for the cross resistance to the 3 
classes of drugs4 . 
The D-test is performed by placing clindamycin and erythromycin 
discs at an edge-to-edge distance of 15 to 20mm and looking for 
flattening of the clindamycin zone nearest the erythromycin disc.5 If D-
test is positive it suggests the presence of an erm gene that could result in 
clindamycin resistance. 
Strains with inducible clindamycin resistance are difficult to detect 
in the routine laboratory as they appear erythromycin resistant and 
clindamycin sensitive in vitro when not placed adjacent to each other. In 
such cases, in vivo therapy with clindamycin may select constitutive erm 
mutants leading to clinical therapeutic failure. But mutations in the 
promoter region of erm gene allows the production of methylase without 
an inducer.  These mutants are stably erythromycin and clindamycin 
resistant (Constitutive resistance). 
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MRSA constitute a major health care problem with a strong 
potential for dissemination and high rate of mortality and morbidity. So 
the availability of sensitive and specific methods for detecting antibiotic 
resistance in these pathogens accurately has become a significant tool in 
clinical diagnosis.   
In PCR by amplification of the mecA gene, MRSA is 
detected.PCR is highly, sensitive, and specific. But it requires advanced 
equipments & moreover it is costly. So it is not possible for routine 
testing in clinical laboratories.Incidence of clindamycin resistance in 
MRSA isolates varies widely by hospital and geographic region 2.  
Errors in the detection of methicillin resistance can have serious 
adverse clinical consequences.  False susceptibility results may result in 
treatment failure and the spread of MRSA if appropriate infection control 
measures are not applied. Conversely, false resistance results may 
increase healthcare cost following unnecessary isolation precautions and 
may lead to overuse of glycopeptides.  
 For detection of methicillin & clindamycin resistance exactly and fastly 
disc diffusion can be used as a screening tool.  It is important to treat the 
infected patients with correct antibiotic so that MRSA is controlled in the 
hospital environment.  
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AIMS AND OBJECTIVES 
1. To isolate and identify staphylococcus aureus by gram staining, 
conventional culture methods and biochemical reactions. 
2. To screen for Methicillin Resistant Staphylococcus aureus by disc 
diffusion method with cefoxitin and oxacillin discs. 
3. To determine the prevalence of inducible Clindamycin resistance 
(iMLSB) and constitutive clindamycin resistance (cMLSB) in 
Methicillin Resistant Staphylococcus aureus isolates using 
erythromycin and clindamycin discs in‘D’test in our geographic 
area. 
4. To compare inducible clindamycin resistance with constitutive 
resistance among MRSA. 
5. To ascertain the relationship between MRSA and clindamycin 
resistance. 
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HISTORY 
• Von Recklinghausen in 1871 observed Staphylococci in human 
pyogenic lesions6. 
• Alexander Ogston a Scottish surgeon was the first to publish the 
observations on Staphylococcal infections between 1880 and 1882. He 
recognized the role of staphylococci in abscess 7. 
• Rosenbach in 1884 named Staphylococcal strains from pyogenic 
lesions as Staphylococcus aureus as it produced golden yellow 
pigment. He separated the genus Staphylococcus into Staphylococcus 
aureus and Staphylococcus albus. 
• Staphylococci and Micrococci were positioned in genus Micrococcus 
by Zopf.   But Flugge separated the genus Staphylococcus and genus 
Micrococcus 8. 
• A French medical student, Ernest Duchesne, in 1886 found that 
Staphylococci aureus colonies could be lysed by the mold  Penicillium 
notatum7. 
• The value of coagulase test to identify staphylococcus aureus was 
brought to attention by Von Daranyi in1925 8. 
• Bacteriologist Alexander Fleming in 1929 published his  observation  
on lysis of staphylococcus aureus in the vicinity by Penicillium mold 
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which contaminated his culture at St. Marys hospital laboratory in 
London9. 
• In 1943, a large-scale production of the penicillin began in the United 
States of America7. 
• Kirby in 1944 described Penicillin resistant staphylococcus aureus 
(PRSA) for the first time 10. 
• The drug vancomycin means "vanquished". In 1950 it was developed 
from soil samples in the jungles of Borneo island 7. 
• Evans et al in 1955 proposed separating Staphylococci from 
Micrococci on the basis of oxidation fermentation test. The 
Staphylococci is aerobic and facultative anaerobic whereas 
Micrococci is an obligatory aerobe 8. 
• In 1956 erythromycin resistance emerged 4. 
• In 1959, world's first semi-synthetic penicillin, the methicillin was 
first marketed to counter the spread of PRSA following which 
different derivatives, like oxacillin were produced.7. 
• Jevons11 first reported MRSA in 1961 in England2,7. 
• Silvestry and Hill 1965 based on DNA composition clearly     
differentiated Staphylococci from Micrococci. 8. 
• McGehee et al  in 1969, has reported  the ineffectiveness  of 
clindamycin  when treating erythromycin resistant Staphylococci12,15. 
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• Cato and Stackebrandt in 1989 tentatively placed Staphylococci in the 
family of Bacillaceae of the order Bacillales 8. 
• In the 1990s, semi synthetic Macrolides with improved 
pharmacokinetics and tolerability developed 4. 
• In1997, the Mu 50 first strain of Vancomycin intermediate 
Staphylococci aureus (VISA) was reported from Japan 13. 
• Kuroda et al in 2001 first reported the whole genomic sequences 
of S.aureus 14  . 
•
 A disc diffusion method was described by Feibelkorn et al in 2003     
for detecting   inducible clindamycin strains of staphylococcus aureus 
in clinical samples. This test was done by placing erythromycin and 
clindamycin discs in close proximity with the interdisc distance of 15-
26mm in Mueller-Hinton agar 15. 
•
 In 2005 Clincal Laboratories Standard Institute standardized the test as 
‘D’ zone test.16. 
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In the pre antibiotic era mortality due to Staphylococcus aureus 
infection was high. The miracle drug penicillin when introduced had 
good impact. But this did not last long, because of the emergence of 
penicillinase producing Staphylococcus aureus. Methicillin was 
introduced in 1961.Soon both CA-MRSA and HA-MRSA became a 
growing problem to the general public in every region of the world. 
Morphology 
 Staphylococcus aureus belongs to the family of Micrococcaceae. 
Staphylococci means cocci occuring in grape like clusters. (In Greek 
Staphyle means bunch of grapes).This gram positive bacteria is 1µm in 
diameter and is non motile. It is an aerobe and facultative anaerobe. The 
genome of Staphylococcus aureus is around 2.8 Mb and contains 2500 
genes. 
Staphylococcus aureus cell wall contains peptidoglycan and 
teichoic acid. Peptidoglycan has crosslinked polymers of N-acetyl 
glucosamine and N-acetyl muramic acid. The adherence of 
Staphylococcus aureus to mucosal surfaces is by teichoic acid. Moreover 
it provides rigidity to cell wall17. Some strains produce exopolysaccharide 
which helps in adherence of organism to host cell and prevents 
phagocytosis. It is occasionally capsulated. 
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Cultural characteristics 
In nutrient agar, Staphylococcus aureus colonies are 1-3mm in 
diameter smooth, low convex, densely opaque with a entire edge and of 
butyrous consistency. Pigmentation ranges from cream through buff to 
gold and is characteristic. Pigmentation is enhanced by prolonged 
incubation as well as when culture plates are left at room temperature.  
Staphylococcus aureus tolerates the concentrations of sodium chloride at 
which other bacteria are inhibited.         
In blood agar beta haemolysis is observed. In Mannitol salt agar 
colonies are of 1mm diameter surrounded   by yellow zone due to acid 
production from mannitol. The selective media available for isolating 
staphylococcus aureus include Mannitol salt agar, Lipase– salt – mannitol 
agar, Phenyl ethyl alcohol agar, Columbia Colistin Nalidixic acid (CNA) 
agar and Baird –Parker agar base 18, 19. 
Biochemical reactions 
Catalase test, Slide coagulase and Tube coagulase tests are 
positive. Staphylococcus aureus is the only species of staphylococcus 
which ferments mannitol. Methyl Red and Voges Prosakeur tests are 
positive. Staphylococcus aureus hydrolyses DNA and produces 
phosphatase. It reduces tellurite to form black colonies in Potassium 
11 
 
tellurite medium. Urea is hydrolysed and gelatin is liquefied. Indole test 
is negative 18. 
Pathogenesis 
The Peptidoglycan and teichoic acid in cell wall are virulence 
factors. Staphylococcus aureus secretes toxins and enzymes which plays a 
role in virulence. Alpha, beta, gamma and delta toxins provokes cell 
destruction. Destruction of phagocytes is mediated by leucocidin. 
Clumping factor, Coagulase and hyaluronidase helps in invasion 
and existence in tissues. These virulence factors are responsible for 
wound infections, as well as skin infections. Several exotoxins like Toxic 
shock syndrome toxin, exfoliative toxin, and enterotoxin are also 
produced. These potent toxins cause systemic effects 20. 
Clinical syndromes 
MRSA is defined as the strains of staphylococcus aureus resistant 
to the isoxazoyl penicillins such as methicillin, oxacillin, nafacillin and 
flucloxacillin. Staphylococcus aureus infections are classified as CA-
MRSA infections and HA-MRSA infections. CA-MRSA secretes a toxin 
Panton-Valentine leucocidin causing infections in healthy individuals. 
CA-MRSA is frequently susceptible to a wide range of antibiotics than 
hospital strains. According to Center for disease control and prevention 
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people who satisfy the following criteria, are said to be infected with CA-
MRSA. 
1. Diagnosed in the outpatient setting as MRSA infected. 
2. Culture for MRSA must be positive within 48 hours of admission 
in the hospital. 
3. No medical history of colonization, hospitalisation, surgery or 
dialysis. 
4. No permanent indwelling catheters or medical devices passing into 
the body through the skin 21. 
Hospital acquired MRSA infection is defined as, occurring in a 
patient whose MRSA isolate was cultured more than 48 hours after 
admission or who has a history of hospitalization, surgery, dialysis or 
residence in a long term health care facility within six months prior to the 
culture date or had an indwelling intravenous line, catheter or any other 
percutaneous medical device present at the time of culture. 
CA-MRSA infections occur both in healthy person and in those 
with known risk factors. Furuncles, impetigo, abscess and cellulitis are 
some of the common skin and soft tissue infections. Severe illness like 
necrotizing pneumonia is reported in patients who has undergone 
tracheostomy or in patients with prolonged intubation. Invasive 
procedures and use of resistant antibiotics results in bacteremia. Other 
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serious infections are endocarditis, septic arthritis, osteomyelitis, 
meningitis, and abscess in liver and spleen. Rarely dissemination to 
urinary tract occurs through bloodstream or by ascending infection from 
urethral meatus. Even pyelonephritis has been documented in some cases. 
Toxin mediated food poisoning, toxic shock syndrome and 
staphylococcal skin scalded syndrome can also occur. 
HA-MRSA infections can include above diseases but surgical 
wound infections and bacteraemia associated with intravenous devices 
are common. Infections associated with cerebrospinal fluid shunts, 
prosthetic joints and vascular grafts and ventilator associated pneumonia 
are also seen with HA-MRSA infections 22. 
Epidemiology 
MRSA was 1st reported in United Kingdom and later on from 
Japan, Europe, and Australia. Waness A. 2010 has documented that 
MRSA has been prevalent in livestock animals and slaughter houses in 
countries like, Canada, Europe and Singapore. MRSA has been found in 
seawater in American beaches7. 
In Europe highest prevalence of   HA-MRSA was reported in 
Portugal (54%), followed by Italy (43-58%) and Netherlands 2%.1 
Prevalence rate ranges from 2% in Netherlands and Switzerland to 70% 
in Japan and Honkong 23. 
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Lahari Saikia et al 2009 has reported that in India the Prevalence 
rate of MRSA is 31% and 38.56% in Tamil Nadu and New Delhi 
respectively. In some studies the rate is found to be low in Nagpur 
(19.56%) & high in Indore (80.89 %) comparatively24. 
Lakshman Swamy Parasa et al 2010 reported the incidence of 
MRSA in India as 32.8%-51.6% during the period of 1994-2001. Some 
studies have reported a prevalence of 39.50% in south Gujarat, 38.44% in 
a tertiary care hospital, North India. MRSA prevalence has been reported 
as 52.9% in Assam, 24% in Chandigarh, and 24% in Vellore.23 The 
prevalence of HA-MRSA in South India hasbeen reported as 31.1% in the 
study of Poonam Sood Loomba et al 2010.1 The prevalence varies by 
geographical location, patient age, and bacterial susceptibility profile. 
30% patients colonise MRSA on nose. In Mathan et al study in 
2009, out of 403 carriers the colonization site of MRSA were 78.5% in 
nose alae, 85.6% in nose and throat and 98% in perineum.  Some, report 
that children and young adults affected by skin and soft tissue infections 
were likely to be carriers. The carriage rate of MRSA in health workers, 
inpatients, and outpatients was 1.8%, 15.6%, and 3.8% respectively. The 
carriage of MRSA was more in inpatients. Overall carriage rate was. 5%. 
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According to some studies 6-50% of health workers working in burns and 
intensive care units are nasal carriers25. 
William J Peppard et al 2009 has reported CA-MRSA in athletes, 
prison inmates, men who have sex with men, military people, drug users 
and children in day care centers, due to crowded living conditions & poor 
personal hygiene. Children less than 2 years, adults more than 65 years of 
age and homeless persons are prone for MRSA infection 21. 
Tony Beavers May et al 2004 adds prior antimicrobial use, HIV 
infection and MRSA colonization of family members as some of the 
predisposing factors26 .MRSA remains a major pathogen in nosocomial 
infections in developing countries. Shantala et al 2011 has documented 
32.5% MRSA isolates with inducible clindamycin resistance. Different 
places of India have reported inducible clindamycin resistance in 30% to 
64% of the MRSA isolates27. 
Mukesh Patel 2006 states diabetes mellitus, renal dysfunction, 
postsurgical status and malignancy, are some of predictors of inducible 
clindamycin resistance. Neutropenia, trauma, burns and organ transplant 
also adds to predictors of inducible clindamycin resistance. The 
prevalence of inducible clindamycin resistance in CA-MRSA in children 
is decreasing over time. This may be due to the expansion of MRSA 
clones lacking genes responsible for inducible clindamycin resistance 28. 
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The spread of MRSA between patients is called cross-infection. 
However, these patients may develop infections if the MRSA enter the 
body with breaks in their skin due to wounds, indwelling catheters, 
contaminated equipment or via environment. Epidemic MRSA may also 
spread between hospitals, presumably when colonised patients or staffs 
move from one hospital to another. 
In India, spreading of CA-MRSA was probably due to 
overcrowding and poor personal hygiene. Although it mainly manifests in 
severe soft tissue and skin infections requiring surgical drainage, it is now 
becoming pronounced in bacteremia affecting neonates, especially from 
lower economic sections, and breast abscesses in lactating mothers. It is 
becoming increasingly common in urban areas. Sheetel Verma et al 2000 
reports that MRSA is common in intensive care units and burns unit29 
.MRSA accounts for 40% to 70% of staphylococcus aureus infections in 
intensive care units10. P.U.Krishnan et al 2002, has documented 65 
isolates of MRSA from patients and health workers working in burns 
units, at St.Johns Medical college Hospital Bangalore, India11. 
In addition to the United States CA-MRSA strains have been 
reported from Canada, Asia, South America, Australia Europe, Norway, 
Netherlands, Denmark, and Finland. Globally, CA-MRSA strains show 
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remarkable diversity in the number of different clones that have been 
identified. The resistance to penicillin by CA-MRSA was the first wave 
of antibiotic resistance which began in mid 1940s. USA 400 clone, causes 
community onset disease among Indigenous populations in Alaska and 
the Pacific Northwest and was isolated from the paediatric cases prior to 
2001. A second epidemic clone, USA300, emerged between 1999 and 
2001, and now causes the vast majority of CA-MRSA infections in the 
United States. Among the MRSA clinical isolates is the archetypal strain 
COL, isolated from a patient in Colindale, United Kingdom in 
1960.Iberian and Rome clones constituted the third wave of antibiotic  
resistance30 .Marta aires et al in 2001 describes Iberian, Brazilian, 
Pediatric, and Newyork-Tokyo clones in addition at international level31. 
Phage typing is an important epidemiological investigation to identify 
MRSA, which is done by 23 internationally accepted phages 32. 
Mechanism of resistance: 
Staphylococcus aureus is susceptible to most antibiotic. Resistance 
to antibiotics is acquired by transfer of genes from outside sources, and 
chromosomal mutation. Antibiotic selection is also to be considered. 
Genes responsible for resistance mechanism is either present on the 
chromosome or on a plasmid. Antibiotic resistant genes can be 
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transferred by Plasmid. Conjugation is the most common method of 
transfer of resistant genes. Transposon is a genetic factor that carries 
portions of plasmid from one organism to another. 
The resistance mechanism is called constitutive if it is expressed 
continuously even if an inciting challenge is available or not. But in some 
genes it must be induced by exposure to the challenging substance. 
Uniform expression of resistance is homogenous expression. But if only a 
small fraction of bacteria expresses the resistance it is called 
heterogenous resistance. It is very difficult to identify this kind of 
resistance in the clinical laboratory. 
Methicillin: 
MRSA is resistant to all currently used betalactam antibiotics. 
Betalactam antibiotics are penicillins,cephalosporins and carbapenams. 
They constitute same structure and mechanism of action. Betalactum 
antibiotics inhibit bacterial cellwall peptidoglycan synthesis 9. 
Methicillin, oxacillin and flucloxacillin are semisynthetic 
penicillins derived from 6-aminopenicillanic acid and they are 
penicillinase resistant33. These bactericidal drugs are administered by 
parenteral route and can’t be administered to patients with a history of 
hypersensitivity reaction to penicillin. 
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Cefoxitin is a cephamycin produced by Streptomyces lactum 
durans34 .The cephamycins are similar to cephalosporins but have a 
methoxy group at position 7 of the betalactum ring of the 7 amino 
cephalosporanic acid nucleus. This is a potent inducer of mecA gene35   . 
Cefoxitin is a surrogate marker of methicillin resistance. Cefoxitin disc 
diffusion tests and PCR have similar sensitivity and specificity. The 
simple ‘D’test is mandatory for all clinical laboratories to detect 
clindamycin resistance2. 
The expression of methicillin resistance in S.aureus due to acquired 
penicillin binding protein PBP2a which is 78 KDa with 668 aminoacids 
possessing both transglycosylase, transpeptidase enzymes involved in 
disruption of final step of peptidoglycan synthesis of bacterial cellwall36. 
PBP2a is encoded by mecA gene,origin of which is not known. mec A 
gene is located within larger region of chromosome, the staphylococcal 
cassette chromosome mec region(SCCmec)(21-67kb).The basic elements 
of SCCmec are the mecRI- mec I-Pbp2a region and ccrA.Mobility of  
SCCmec is conferred by ccrA and  ccrB genes.Nosocomial isolates are 
multidrug resistant due to accumulation of plasmids & transposons in  
SCCmec .As they  are larger in size not transfered by bacteriophages 1. 
SCCmec is classified into types I, II, III, IVa, IVb and V. Types I, 
II, III are found in nosocomial infections. Type IV is found in CA-
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MRSA. Namita D’ Souza et al 2010 has classified SCCmec additionaly 
into type VI, VII,which are also found rarely. The mec A gene complex, 
cassette chromosome recombinase complex (ccr complex) and junkyard 
variation results in characterization of SCCmec element 37. 
Other genes like fem (factor essential for methicillin resistance), aux 
(auxillary gene), BlaI gene which are involved in the formation of 
Staphylococcus aureus cellwall also influence the expression of 
methicillin resistance 1. 
Disc diffusion test for detection of Methicillin resistance: 
For detection of Methicillin resistance, cefoxitin disc diffusion test 
and oxacillin disc diffusion test are used.0.5 McFarland standard 
suspension of the staphylococcus aureus isolate is made and lawn culture 
done on Muller Hinton Agar plate .A 30 µ of cefoxitin and 1 µ of 
oxacillin are placed and plates are incubated at 37º C for 24 hours and 
zone size are measured . Oxacillin disc diffusion test must be read in 
transmitted light38. 
In January 2007 CLSI published inhibition zone diameter for 
Cefoxitin as follows. Zone diameter of ≥ 22mm is reported methicillin 
susceptible and ≤ 21mm considered methicillin resistant and for oxacillin 
of ≥13mm is reported methicillin susceptible and ≤10 mm is considered 
as methicillin resistant 34.  Poonam Sood Loombaetal 2010 explains that 
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disc diffusion test using cefoxitin is easy to read. It gives clearer end 
points than oxacillin1. Oxacillin is frequently misinterpreted as 
susceptible due to haziness. False susceptibility of 4.4% has been 
reported with oxacillin disc diffusion test 34. 
Environmental condition like PH, temperature and salt 
concentration also decides the expression of methicillin resistance39,40. In 
R.Skov et al 2006 suggest that incubation temperature influences zone 
diameter and MIC for staphylococcal strains that are methicillin resistant 
.Detection of MRSA by cefoxitin disc is not much affected by 
temperature variation. But for oxacillin the temperature should not exceed 
37ºC.  Incubation at 30 º C was associated with lower accuracy. 
Increasing the duration of incubation from 18 hours to 24 hours did not 
improve accuracy41. Incubation temperature of 37ºC for 24 hours in disc 
diffusion test is trustworthy1.  Isolates resistant to both cefoxitin and 
oxacillin had an MIC 0.5-2µg/ml. As per CLSI criteria MIC less than 
2µg/ml is interpreted as MSSA35. 
So results of either cefoxitin disc diffusion or MIC tests can be 
used to predict mec A mediated oxacillin resistance. Based on cefoxitin 
results, oxacillin should be reported susceptible or resistant. Susceptibility 
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or resistance to betalactam antibiotics may be deduced from testing only 
penicillin and either cefoxitin or oxacillin42. 
K.B. Anand et al 2009 describes that the mecA gene positive 
staphylococcus aureus isolates are expressed either as homogenous or 
heterogenous resistant strains. mecA gene is expressed  in  low level in 
heterogenous resistance . On disc diffusion testing these strains appears 
as susceptible to oxacillin43. The gene mecA is expressed only in 1in 
105cells and its expression is rapid if betalactam bind to the surface 
receptors for the derepression of mecA. (Henneth H, Randetal 2004)44 . 
Cefoxitin disc diffusion test is a superior test to oxacillin disc 
diffusion test as it has higher sensitivity and specificity38. Anila A. 
Mathews et al describes methicillin resistance detected by oxacillin 
diffusion test could be false positive due to hyperbetalactamase 
production. These isolates were sensitive to cefoxitin and negative for 
mecA gene. These isolates were named BORSA (Borderline oxacillin 
resistant Staphylococcus aureus). These strains may evolve to fully 
resistant ones in due course of time under antibiotic pressure 35. 
Oxacillin resistant strains are resistant to all penicillins, 
cephalosporins, monobactam, other betalactams /betalactamase inhibitor 
combinations, and carbapenams. Penicillin susceptible staphylococcus are 
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also susceptible to other penicillins,beta lactam/beta lactam inhibitor 
combinations, and carbapenam. Oxacillin resistant staphylococci are 
resistant to all currently available betalactam antibiotics with exceptions 
of newer cephalosporins with anti-MRSA activity42,45. 
Other than disc diffusion method, different methods are available 
for the detection of MRSA namely broth dilution method, agar dilution 
method and epsilometry test46. Mannitol salt agar medium supplemented 
with oxacillin and MRSA select medium, are some of the culture media 
available for MRSA detection47,48. In Oxacillin resistant screening agar 
medium, Mueller Hinton agar supplemented with 4% Nacl and 6mg/ml of 
oxacillin is used for detecting MRSA49. Immunochromatographic test and 
Latex agglutination test is also used for detecting PBP2. PCR detects mec 
Agene but it is very costly. So it is not possible to perform it as a routine 
procedure in clinical laboratories36. Serhat Unal states that mecA can be 
detected by DNA hybridization. Rapid cell lysis technique was 
established for the release of DNA from staphylococcus isolates39. 
Macrolide and Lincosamide  
MRSA has left as with few therapeutic alternatives to treat.The 
major alternative to penicillins and cephalosporins are Macrolide –
Lincosamide- Streptogramin B (MLSB) antibiotics for the treatment 
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staphylococcus. Macrolides have been known for many years. The 
evolution of the macrolide class has been marked, in 1990s, especially 
with production of semisynthetic macrolides with improved 
pharmacokinetics and tolerability. 
Macrolide and lincosamide antibiotics are chemically different but 
have a similar mode of action. They are active against gram-positive 
staphylococci. Macrolides have two or more amino or neutral sugars.The 
sugars are attached to a lactone ring whereas lincosamides 
(eg.,clindamycin and lincomycin) are devoid of a lactone ring. 
Clindamycin and macrolides act at sites which are in close 
proximity.Increasing knowledge of the molecular mechanisms of 
resistance to macrolides has led to the design of ketolides which are 
active against certain types of erythromycin resistant organisms. 
Macrolides and lincosamide antibiotics are bacteriostatic. They inhibit 
protein synthesis by binding to 50s ribosomal units of the organism 
reversibly. 
Clindamycin is used to treat staphylococcus aureus infection as it 
has excellent pharmacokinetic properties. James et al 2oo5 states that  
clindamycin is an attractive option for skin and soft tissue infections 
because this drug is available in oral (90% bioavailability) and 
intravenous formulations. Unlike beta lactam it is not impeded by high 
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bacterial burden at infection site. Staphylococcal toxins and virulence 
factors are inhibited by this drug12 .It is advisable to use clindamycin in 
necrotizing skin and soft tissue infections as it has the capacity to reduce 
toxin expression 50. Clindamycin has good penetration into various tissues 
including bones except CSF1. . 
Clindamycin is a congener of lincosamin. It is a derivative of the 
aminoacid trans L- 4 –n-propyl hygrinic acid attached to octose  which 
has sulfur. It binds to the 50 s ribosomal unit of bacterial ribosomes and 
thus inhibiting bacterial synthesis. It is completely absorbed following 
oral administration. Clindamycin palmitate is an oral preparation for 
paediatric use.The phosphate ester of clindamycin when given 
parenterally is hydrolyzed in vivo to an active drug. Drug crosses the 
placental barrier.90% is bound to plasma proteins. This accumulates in 
inflammatory cells like leucocytes and macrophages. It is metabolized as 
N-dimethyl clindamycin, and sulfoxide and finally excreated in urine and 
bile.MIC of clindamycin 0.25-8g/ml. MIC of clindamycin ≤0.5 g/ml was 
considered sensitive and MIC ≥ 4g/ml was taken as resistant3. 
Mechanism of Clindamycin resistance: 
Resistance of staphylococcus aureus to MLSB antibiotics can occur 
by different mechanisms. 
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1. Macrolides Streptogramin resistance 
The first involves macrolide active efflux and is relatively 
common. A specific efflux pump is encoded by the gene msrA in 
staphylococci .This energy dependent pump effectively expels macrolides 
from the bacterial cell before they can bind to their target site on the 
ribosome. This mechanism of resistance creates resistance, but only to 
macrolides, azalides (e.g., Azithromycin and group B streptogramins - 
quinupristin) . Lincosamides (e.g., clindamycin and lincomycin) are not a 
substrate to this macrolide efflux pump4,12. 
2. MLSB resistance ( Macrolide-Lincosamide-Streptogramin B) 
The second mechanism of resistance to macrolides in 
staphylococci involves modification of the drug binding site on the 
ribosome. This results in resistance to macrolides (and 
azalides),lincosamides, and group B streptogramins and is commonly 
referred to as “MLSB resistance” coded by the erm gene.MLSB resistance 
can be either constitutive (cMLSB) or inducible (iMLSB). In vitro 
staphylococcal isolates with constitutive resistance are resistant to both 
erythromycin and clindamycin , while isolates with inducible resistance 
are resistant to, but appear to be susceptible to clindamycin 4,12,27. 
27 
 
3. P. Sireesha et al 2012 states that third mechanism of resistance to 
lincosamides in staphylococci is by rare lnu gene which causes chemical 
alteration resulting in inactivation of the drug 3,4. 
The inducible Clindamycin resistance and constitutive clindamycin 
resistance occurs through the second mechanism of resistance involving 
modification of the drug binding site on the ribosome, as mentioned 
above. 
The MLSB phenotype is encoded by erm (erythromycin ribosome 
methylase) genes in staphylococci. The erm(A) genes are mostly present 
in methicillin resistant staphylococcus aureus and are borne by 
transposons related to Tn554, whereas erm (C) genes  which are present 
in methicillin-susceptible staphylococcus aureus  are borne by plasmids 4. 
There is a single adenine in nascent 23S rRNA, which is part of the large 
(50S) ribosomal subunit. erm protein dimethylates the adenine. The 
A2058 residue is located within a conserved region of domain V of 23S 
ribosomal RNA.  It plays a role in the binding of MLSB antibiotics. As a 
outcome of methylation, binding of erythromycin to its target is impaired. 
The overlapping binding sites of macrolides, lincosamides,and 
streptogramins B in 23S rRNA explains the  cross-resistance to the 3 
classes of drugs 12,51. 
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Expression of MLSB resistance can be constitutive or inducible. In 
inducible resistance, the bacteria produce inactive mRNA which is unable 
to encode methylase .It is activated in the presence of macrolides which 
are inducers ,but  not by lincosamides and Streptogramin B which are non 
inducers. This   leads to rearrangements of mRNA, which allow 
ribosomes to translate the methylase coding sequence4. 
The messanger RNA in its 5’ end constitutes leader peptide along 
with a set of inverted repeats. This forms a hairpin like structure. This, by 
base pairing sequesters the initiating sequences (initiating codon) for 
methylation.The inducer macrolide binds to the ribosome when leader 
peptide is translated. Now there is destabilization of hairpin like structure. 
The initiating sequences are exposed to the ribosomes and there is 
translation of methylase52. According to Claire Daurel et al 2008 the 
regulatory region of ermA is longer.There is one leader peptide and four 
inverted repeats in the regulatory region of ermC.The regulatory region of 
ermA has two leader peptide and six inverted repeats .This leads to the 
difference in the structure of attenuator leads and therefore different 
patterns of MLSB inducible resistance are observed4,52. In constitutive 
expression, active methylase mRNA is produced in the absence of an 
inducer 53 .Additional changes in the 5’ upstream sequences by deletion, 
duplication and mutation leads to constitutive resistance12. 
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Method of detection of Clindamycin resistance 
D-test (Double-disk diffusion test)  
The inducible Clindamycin resistance is not detected by standard 
broth microdilution method, automated susceptibility testing devices, 
standard disc diffusion test or E test12. So the procedure for clindamycin 
resistance testing was introduced in January 2004 by National committee 
for Clinical Laboratory Standards Institute. (Now CLSI)54. 
In this disk diffusion test, for detecting clindamycin resistance, the 
truncated zone of inhibition to the drug clindamycin resembles the letter 
‘D’. So this test was called as ‘D- test’ (James et al 2oo5)12. 
Procedure: 
Clindamycin (2 µ) and erythromycin (15µ) discs  are placed 15 
mm (edge to edge ) apart on Mueller-Hinton agar that has been inoculated 
with a standardized (0.5 MacFarland) suspension of staphylococcus  
aureus and  incubated overnight  at 37 ºC. D test was read in reflected 
light55. 
Following were observed in disc diffusion results: 
Inducible Clindamycin resistance (iMLSB): 
It is very important to find out the emerging Clindamycin 
resistance patterns to institute proper management to HA-MRSA and  
CA-MRSA . 
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Staphylococcal isolates showing resistance to erythromycin (zone size ≤ 
13mm) but sensitive to clindamycin (zone size ≥ 21 mm) shows two 
distinct induction phenotypes. 
1. Sensitivity to clindamycin results in a D-shaped blunting of the 
circular zone of inhibition around the clindamycin disc on the side 
facing the erythromycin disc. A clear, D-shaped zone of inhibition 
round the clindamycin disc was designated as the D phenotype. 
2. D-shaped zone containing inner colonies growing up to the 
clindamycin disc was designated as D+56,3. 
N.Pal 2010 states that both D and D+ were considered positive for 
inducible clindamycin resistance56. 
MS phenotype:  
The msrA gene confers the so called MS phenotype (resistance to 
erythromycin, inducible resistance to streptogramins and susceptibility to 
clindamycin) by efflux.  Erythromycin   resistant (zone size ≤ 13mm) but 
sensitive to clindamycin showing circular zone of inhibition around 
clindamycin with the zone size of   ≥ 21mm was called as MS 
phenotype55. 
Constitutive resistance (cMLSB): 
In constitutive resistance Staphylococcal isolates shows 
erythromycin resistance (zone size ≤ 13mm) & clindamycin resistance  
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(zone size ≤ 14 mm). Clindamycin leads to selection of constitutive 
mutants at frequency of 107CFU3 .According to P.Sireesha et al 2012 D 
and D+ were considered as constitutive resistance3. 
S (susceptible) phenotype: 
Staphylococcal isolates sensitive to both erythromycin & 
clindamycin. Strains showing higher MIC inspite of being sensitive to 
both erythromycin & clindamycin shows heteroresistance as possibility. 
Further studies are done to find out other mechanisms of resistance 
involved. 
HD phenotype (Hazy D zone) 56,3 
This type shows 2 different zones, one zone is a light hazy growth 
around clindamycin disc and the other is with heavy growth in the shape 
of letter ‘D’. 
So at present, disc diffusion test is the preferred method for testing 
staphylococcus aureus isolates for inducible clindamycin resistance. 
Feibelkorn et al 2003 has reported 100% sensitivity in detecting 
iMLSB resistance on performing disc diffusion test using 15- 26 mm 
interdisc distance between erythromycin 30µg and clindamycin 2 µg 
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discs.Whereas only 97% sensitivity has been documented with 26-28 mm 
interdisc distance 15. 
Mathew V.N.O. Sullivan et al 2006 recommended an edge to edge 
distance of 15mm in disc diffusion test for detecting iMLSB resistance. 
This is because , on performing D-test  an error rate of 18.2% was found 
with 22mm interdisc spacing between erythromycin and clindamycin 
discs in MRSA isolates51. 
G.S.Ajanta et al 2008 informs that ideal interdisc spacing between 
the erythromycin and clindamycin is not yet clear. But false positivity 
was not reported with 15mm of spacing. Clinical and Laboratory 
Standards Institute has suggested 15-26 mm of interdisc 
spacing.57According to Clarece J. Fernandes 2007 when compared to 
genotypic analysis disc diffusion test have high sensitivity and specificity 
but if the disc separation distance is too wide false negative results may 
occur58. 
Christine D Steward et al 2005 has stated that clindamycin 
resistance is effectively induced by erythromycin59. Mukesh Patel et al 
2006 states that inducible clindamycin resistance exihibiting strains have 
high rate of undergoing mutation to constitutive resistance spontaneously. 
D-test was done in 402 staphylococcal isolates, in which 280 were MRSA 
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and 122 were MSSA. Out of 280 MRSA, 139 MRSA showed inducible 
clindamycin resistance. Likewise Out of 122 MSSA, 73 MSSA showed 
inducible clindamycin resistance. 56% HA-MRSA and 41 % CA-MRSA 
have contributed to positive D test. There was low prevalence of iMLSB 
resistance in CA-MRSA which has favoured the use of clindamycin as 
outpatient treatment 28. 
Angel et al have not found any constitutive MLSB resistance in 
staphylococcus aureus strain60. Sireesha et al 2012 states HD phenotype is 
considered as constitutive MLSB resistance.1 Shailesh kumar et al 
reported 2.9% of constitutive resistance in MRSA. 61 This contrasts with 
the Korean study where constitutive resistance was reported in majority 
(79%) in MRSA62. 
Dr.R.Vasanthi et al 2012 reported sensitivity of D test performed at 
15 mm distance spacing correlated 100% with detection of erm & msr 
genes by PCR.  Moreover iMLSB resistance is higher than constitutive 
resistance in HAMRSA. Inducible clindamycin resistance  is higher in 
MRSA(1.88%) than MSSA (3.5%)63 .In the study by Adebayo et al 2006 
constitutive MLSB resistance was absent in MRSA and one was identified 
in MSSA 54. Dr.Mohanasundaram et al 2011, highlights that iMLSB 
resistance is higher in MRSA (28%) than MSSA (11%)64. This is 
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supported by the Study of Shantala et al 2011 who has documented 
32.3% of   iMLSB resistance in MRSA isolates & 15.38% in MSSA 
isolates27.  Vidyapai et al reported 18.8% of iMLSB resistance in MRSA 
while in MSSA it was 3.5%65. 
V.Gupta et al 2009 has documented 66.67% of iMLSB resistance 
from community and 33.33% from hospital66. Since higher incidence of 
CAMRSA is being reported in outpatient clinic, the Clindamycin 
available in oral formulations has been frequently prescribed. In India 
Gadepelli et al has documented higher rate of constitutive resistance than 
iMLSB resistance. 30% iMLSB resistance in MRSA 10% iMLSB 
resistance in MSSA 38% constitutive resistance in MRSA a15% 
constitutive resistance in MSSA .In the study by V.Gupta et al 2009, 46% 
of constitutive resistance and 20% of   iMLSB resistance has been 
reported in MRSA66. But in MSSA, iMLSB resistance (17.3%) was in 
higher percentage than constitutive resistance (10%).Todd P Levin etal 
2005 reports that in Houstan,among the  children  infected with MRSA 
2.2% of D test positivity was reported. But children in Chicago infected 
with MRSA showed 94% of positive result in D-test 53. 
Clarece J. Fernandes   2007   has described an agar dilution method 
for the detection of inducible clindamycin resistance in staphylococcus 
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aureus 58 .Broth microdilution is also used as a method to detect inducible 
clindamycin resistance 67. 
Other antibiotics of choice in MRSA 
James S. Lewis etal 2005observed that multiple outpatient 
antibiotic regimen of CA-MRSA had a narrow antibiotic resistance 
profile. It is sensitive to non betalactam drugs like clindamycin, 
trimethoprim-sulfamethoxazole and tetracycline, doxycycline, 
minocycline and fluroquinolones12. 
Shaileshkumar et al states majority of MRSA isolates are 
susceptible to clindamycin,vancomycin and linezolid but most of them 
are resistant to trimethoprim -sulfamethoxazole and ciprofloxacin61. 
Tetracycline resistance is exhibited in staphylococcus aureus 
through plasmid mediated tetk, gene encoding efflux mechanism. 
staphylococcus aureus can also be resistant to aminoglycosides due to 
modification of aminoglycosides by enzymes so that they cant bind to 
ribosomes 68. 
Usage of clindamycin & trimethoprim-sulfamethoxazole is 
necessary as there is increase in vancomycin resistance. (Hwan  sublime 
et al 2006)62. 
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Wei Qi et al 2005 have reported that resistance to trimethoprim is 
by mutation of chromosomal gene for dihydrofolate reductase or by 
transposon Tn4003 borne dfr gene 69. 
In the study of Adebayo O Shittu et al, E test macrodilution method 
was performed to find the resistance to vancomycin and teicoplanin 
among MRSA .But none of the MRSA isolates were resistant to both the 
drugs. It was found penicillin and ampicillin were the least effective 
drugs to treat staphylococcus aureus which is a stumbling block for 
antibiotic therapy54. 
67% of iMLSB resistant isolates were susceptible to 
ciprofloxacin.28% of iMLSB resistance isolates were susceptible to 
linezolid and van55. Vancomycin is a glycopeptides which binds to the D-
alanyl- D-Alanine of the peptidoglycan precursor at the cell membrane 
thus inhibiting crosslinking and polymerization of peptidoglycan. First 
strain of Vancomycin-intermediate S. aureus (VISA) was identified in 
Japan in 199610. The second strain of Vancomycin-intermediate S. aureus 
(VISA) JH 9 was isolated from a bacteremic patient in United States in 
200013. Both Mu 50 the homogenous strain and JH 9 heterogenous strain 
were resistant to oxacillin 13 .Following that two additional cases were 
reported from United States First clinical isolate of vancomycin-resistant 
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S. aureus ( VRSA) was reported from United States in 2002 from a 
patient in Michigan 10. 
Marilyn chung et al 2008 observed that MRSA isolates are often 
resistant to penicillin,tetracycline and erythromycin.VRSA isolates were 
resistant to betalactams and glycopeptides.   Ceftobiprole was effective 
against vancomycin resistant MRSA.This new cephalosporin is the active 
form of the prodrug Ceftobiprole medocaril13.               Linezolid is a 
oxazolidinone which is a bacteriostatic. PVL cytotoxin is inhibited by 
linezolid and clindamycin .Chromososmal mutation in gene encoding  
DNAgyrase and topoisomerase IV enzymes is responsible for 
fluroquinolone resistance. Dalbavancin is a semisynthetic lipo 
glycopeptide with a long half life .So once weekly dosage is advised. 
Skin and soft tissue infections can be treated with 
clindamycin,trimethoprim-sulfamethoxazole,doxycycline, tetracycline or 
linezolid. HA-MRSA is treated with intravenous clindamycin, 
vancomycin and linezolid. Clindamycin  and  linezolid are not advised if 
there is infective endocarditis, or if there is a source of  endovascular 
infection. (Catherine etal2011)70. 
Quinopristin-dalfopristin are streptogramin antibiotic used in 
bacteremia and in complicated skin and soft tissue infection. But its use is 
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limited because of the adverse reactions and is given only when 
conventional therapy is not used. In the sameway tigecycline is also used 
in complicated skin and soft tissue infection. Daptomycin is a lipopeptide. 
It is bactericidal by disrupting bacterial cytoplasmic membrane in the 
presence of calcium ions. Combination of daptomycin with oxacillin & 
Betalactam acts in synergy and so may be useful in treating MRSA 
(Henneth H, Randetal 2004)44. Vancomycin, linezolid, quinopristin-
dalfopristin, daptomycin, tigecycline and teicoplanin are used parenteraly.  
Multiple antibiotics which are active against MRSA like telavancin, and 
oritavancin are under development. Iclaprim a dihydrofolate reductase 
inhibitor is also under trial21. 
Nasal decolonization of MRSA in carriers is by applying 
mupirocin, body decolonization is done with chlorhexidine soap along 
with oral antibiotics rifampicin in combination with trimethoprim-
sulfamethoxazole or ciprofloxacin 1. 
Therapeutic options for MRSA have been limited due to 
emergence and spread of multidrug resistant organisms. Therefore 
sensible use of antibiotics is essential. Knowledge of prevalence of 
MRSA & their antimicrobial susceptibility pattern is very important in 
treating patients appropriately. In India where molecular methods are not 
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feasible as routine, the disc diffusion tests helps in detecting drug 
resistance. 
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MATERIALS   AND   METHODS 
Place of study 
The present study was conducted in Coimbatore Medical college 
hospital, Coimbatore. 
Study period 
The study period was for one year from September 2011 to August 
2012. 
Ethical consideration 
Before starting the study the Ethical and Research clearance was 
obtained from Ethical committee of Coimbatore Medical college hospital, 
Coimbatore. 
Sample 
A total of 200 staphylococcus aureus isolates from clinical samples 
including, pus, sputum, blood, vaginal swab and urine were included in 
the study. Samples were received from outpatients and in patients who 
attended Coimbatore Medical college hospital, Coimbatore. 
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Processing of samples 
The received samples were checked for proper labelling with 
Name, Age, Sex  and I.P/ O.P No. of the patient, date and time of 
collection of the sample and processed immediately. Direct smears were 
prepared from sample material like pus, sputum, urine and vaginal swab 
on a clean glass slide. Gram staining was done and examined under 
microscope. The findings were recorded. 
Blood samples sent in brain heart infusion broths were incubated 
for18 -24hours and then subcultured. All the above  specimens were 
inoculated  on to  the nutrient agar plate ,blood agar, and MacConkey 
agar, and  incubated  at  37º C  for 18-24 hours  aerobically and  observed 
after incubation. 
All the suspected colonies were identified by colony morphology, 
gram staining was done and the organism subjected to various 
biochemical tests to identify and characterize them. Further confirmation 
was done by slide and tube coagulase test, and growth on Mannitol Salt 
Agar. 
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Identification tests 
 
Microscopy 
Gram stain   
Colonies from 18 to 24 hour culture was taken from the agar plate 
and a smear was prepared   on a clean glass slide. Then it was air dried 
and heat fixed.  
The smear was overlaid with primary stain 0.5% methylviolet and 
kept for 1 minute and then washed with water. The mordant gram’s 
iodine was applied to the smear and washed with water after1 minute. 
This was decolorized with   few drops of acetone and washed with water 
immediately.  
The  counter  stain,  1:20  dilute  carbol fuchsin  was flooded on the  
smear ,  kept for 1 minute and then  washed  with  water. The smear was 
air dried and then viewed under oil immersion objective. Gram positive 
cocci arranged in clusters were observed. 
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Culture18 
Colony morphology 
Nutrient agar 
Golden yellow pigmented colonies, 1 to 3mm in diameter, circular, 
smooth, low convex and densely opaque with butyrous consistency was 
seen. 
Blood agar 
Colonies surrounded by narrow zone of beta hemolysis was 
identified. 
Mac Conkey agar 
No Growth 
Mannitol salt agar 
This is a selective and indicator medium. The organism was 
inoculated in mannitol salt agar which consists of 1% mannitol, 7.5% 
sodium chloride, and phenol red. The plates were incubated at 37 ºC for 
18-24 hours and then examined. Staphylococcus aureus produced yellow 
colonies surrounded by yellow zone due to acid formation (Mannitol 
fermentation). Staphylococcus aureus ATCC 25923was used as positive 
control. 
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Biochemical reactions 
Catalase test71 
The Staphylococcus aureus produces catalase enzyme which will 
split hydrogen peroxide into water and oxygen. Release of oxygen 
produces the effervescence. 
Procedure 
One ml of 3% hydrogen peroxide was taken   in a clean test tube. 
Few colonies of the test organism were taken from the agar plate with a 
sterile glass rod and immersed in the hydrogen peroxide solution. 
Interpretation 
Catalase test is positive if immediate and sustained effervescence is 
produced. In staphylococcus aureus Catalase test is positive. 
Coagulase test72 
This test confirms staphylococcus aureus isolates. Staphylococcus 
aureus produces the enzyme Coagulase which converts fibrinogen  to  
fibrin that  causes  plasma to clot. Two types of  coagulase  are  produced  
by  staphylococcus aureus.  The free   coagulase   which   converts  
fibrinogen  to  fibrin  by  activating  coagulase  reacting  factor present  in  
plasma is detected by tube coagulase test. 
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Bound coagulase (clumping factor) which converts fibrinogen to 
fibrin with no involvement of clotting factor.It can be detected by 
clumping as seen in the slide test. 
Slide coagulase test 
Two circles were drawn on a clean glass slide with wax pencil. 
With the help of the bacteriological loop the test organism was emulsified 
in drops of saline kept on both the circles to form a smooth milky 
suspension. One suspension was kept as the control and to the other, trace 
of plasma was added by a flamed, cooled, straight inoculating wire. 
Coarse clumping of organisms in suspension, visible to naked eye 
within 10 seconds was considered positive. Absence of clumping in both 
the suspensions was considered as negative. 
Tube coagulase test 
Staphylococcus aureus to be tested was grown in brain heart 
infusion broth  and was incubated overnight  at 37º C .To 1ml of this 
culture, 0.5 ml of undiluted plasma was added. Positive control ATCC 
Staphylococcus aureus and Negative controls ATCC CONS were 
included. All tubes were incubated at 37ºC. Tubes were examined at 1,2 
and 4 hrs for coagulam formation by tilting the tube at 90º. If no 
coagulam is formed at the end of 4 hours, the tubes were reincubated at 
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room temperature for the next 12-16 hours and reexamined for the 
presence of a coagulam. Any degree of coagulam formation was 
considered as positive. If otherwise the the test was considered as 
negative. 
Sugar fermentation test73 
The test is used to determine the ability of an organism to ferment a 
specific carbohydrate which is incorporated in a basal medium and to 
produce acid or acid with visible gas sugar medium with 1% mannitol 
with, bromothymol blue as indicator was used. 
Procedure 
The test media was inoculated with the cultural isolate and 
subsequently incubated at 37ºC for 24 hours. 
Interpretation 
A positive test was shown by yellow colouration of the medium 
due to acid production. 
Methyl red test (MR test) 74 
This test is used to determine the ability of  organisms  to produce  
acids  by  glucose fermentation   through  the  mixed  acid  fermentation  
pathway. 
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Procedure     
One drop from 24 hour brain heart infusion broth culture was   
inoculated in 5ml of MRVP broth.Incubated at 37◦Cfor 48 hrs.  After   
incubation 5 drops of methyl red reagent was added to 5ml of   broth. 
Interpretation 
Bright red colour indicates positive MR test. All Staphylococcus 
aureus isolates were MR positive. 
Voges proskauer test: (VP test) 74 
VP test is used to determine the ability of organisms to produce  
acetoin by  glucose fermentation. 
Procedure 
The  organism  isolated  from   primary  culture  plate   was   
inoculated  in glucose  phosphate  peptone  water and  incubated  for 48 
hrs at 37º C. To 1ml  of  MRVP broth  0.6ml of 5%  alpha naphthol  and  
0.2 ml  of  40%  KOH  were  added  and  shaken  well. Observed for5 
minutes. 
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Interpretation 
A positive test is indicated by the development of red color due to 
acetoin. All staphylococcus aureus isolates were VP test positive. 
Modified Hugh and Leifsons test (O/F test) 75 
Procedure 
Duplicate tubes of semisolid OF medium containing carbohydrate 
with bromothymol blue as indicator are inoculated with bacterial growth 
from 18-24 hour culture by stabbing to a depth of 1cm. One tube was 
overlaid with sterile liquid paraffin,and both tubes were incubated at 
37°C for up to 7 days. 
Interpretation 
Staphylococcus aureus produce acid by fermentation throughout 
the medium in both tubes indicated by yellow colour.  Oxidising 
organism produce acid in the aerobic tube only. 
Indole test76 
This test is done to find the ability of organism to split Tryptophan 
to form the indole. 
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Procedure 
Tryptophane broth was inoculated with one drop from a 24 hour 
brain heart infusion broth culture. Then it was incubated at 37ºC. After 48 
hours 0.5 ml of Kovac’s reagent was added and gently shaked. 
Interpretation 
Pink color ring appears if the test is positive.If the test is negative 
there is no color change. Indole test is negative in staphylococcus aureus 
isolates. 
Urease test77 
The organism produces the enzyme urease, which decomposes the 
urea in the medium by hydrolysis into ammonia and carbondioxide. This 
results in increase of pH, of the medium producing purple pink color. 
Procedure 
The colonies  isolated  from 18-24 hour culture plate  was  heavily 
inoculated over the Christensen’s  urease agar slope and  incubated  at  
37ºC  overnight. 
Interpretation 
All Staphylococcus aureus isolates were urease test positive. 
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Disc diffusion method78 
Inoculum Preparation 
Four to five colonies of the same morphology is selected from an 
agar culture plate. With a  sterile bacteriological loop, the growth was 
inoculated into broth medium which was incubated for 3 to 5  hours  to  
achieve a  turbid  suspension .This is compared with 0.5 McFarland 
standard. 
0.5 McFarland Turbidity standard preparation  
This is prepared by adding 0.05ml of 1% anhydrous BaCl2 to 9.95 
ml of 1% H2SO4 in a test tube, which is sealed and kept in refrigerator. 
Inoculation and incubation 
The sensitivity to common antibiotics was done by Kirby Bauer 
disc diffusion method as recommended by CLSI. Control strains used are 
staphylococcal aureus ATCC -25923 and MRSA -43300. 
A swab was submerged in bacterial suspension and was inoculated 
into, Mueller Hinton Agar plate. The surface of the plate is swabbed in 
three directions so that there is even and complete  distribution of the 
inoculum. Within 15 minutes of inoculation antibiotic discs were applied 
using a sterile forceps. 
The antimicrobial discs used were procured from Himedia. The 
drugs  oxacillin(1µg),  cefoxitin(30µg), penicillin(10u), linezolid(30 µg),   
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vancomycin(30µg) , doxycycline (30µg), amoxyclavulanic acid  (30µg), 
cephelexin(30µg), cotrimoxazole(25µg), cefotaxime(30µg), 
amikacin(30µg), ciprofloxacin(5µg),were  dispensed onto the surface of 
the inoculated agar plate using sterile forceps. 
Each disc was pressed down to ensure complete contact with the 
agar surface. Then plates were inverted for incubation as accumulation of 
moisture leads to interference in test interpretation. 
Incubation is at  37ºC for 24 hrs after which ,  the  zone  of inhibition  
was measured  by using  zone measuring scale  and interpreted  as per  
the  CLSI  standards. Transmitted light was used to examine the light 
growth of methicillin resistant isolates. 
 
Interpretation of disc diffusion test 
Disc diffusion test for detecting Methicillin resistance. 
Oxacillin disc diffusion test38 
Zone diameter of 13mm or   more was taken as sensitive,11 to 
12mm  was taken as  intermediate   sensitive and 10 mm or  less is 
considered as MRSA. 
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Cefoxitin disc diffusion test 
Zone diameter of 22 mm or more was taken as sensitive and 21 
mm or less was considered as resistant. These resistant isolates were 
considered as MRSA. 
‘D’ test3,55,56 
A 0.5 McFarland suspension of staphylococci was inoculated on 
Mueller Hinton agar plate. Clindamycin (2µg), and erythromycin (15µg), 
discs were placed at an edge-to-edge distance of 15 to 20mm, followed 
by overnight incubation at 37oC. 
Description of different types of phenotypes that were looked for: 
Inducible Clindamycin resistance: (iMLSB resistance) 
Staphylococcal isolates showing resistance to erythromycin (zone 
size ≤ 13mm) and a clear, D- shaped zone of inhibition round the 
clindamycin disc was designated as the inducible clindamycin resistance 
(D phenotype). 
MS phenotype 
In this phenotype Staphylococcal isolates were erythromycin 
resistant (zone size ≤ 13mm) .But sensitive to clindamycin (zone size ≥ 
21mm) showing circular zone of inhibition around it. 
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Constitutive resistance (cMLSB resistance) 
Staphylococcal isolates resistant to erythromycin (zone size ≤ 
13mm) and resistant to clindamycin (zone size ≤ 14 mm) were brought 
under this phenotype. 
Susceptible phenotype(S phenotype) 
Staphylococcal isolates sensitive to both erythromycin (zone size ≥ 
23mm) and clindamycin (zone size ≥ 21mm) were categorized in this 
phenotype. 
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Antimicrobials with interpretation of zone size 
 
 
Antimicrobial agent   (µg) 
Inhibition zone in mm 
Resistant ≤ Intermediate Sensitive ≥ 
Oxacillin         1 µg 10 11-12 13 
Cefoxitin         30µg 21 - 22 
Erythromycin  15µg 13 14-22 23 
Clindamycin      2µg 14 15-20 21 
Linezolid          30 µg - - 21 
Vancomycin  30 µg - - 15 
Amikacin         30 µg 14 15-16 17 
Doxycycline 30 µg 12 13-15 16 
Cotrimoxazole  25 µg 10 11-15 16 
PenicillinG   10 units 28 - 29 
Amoxyclavulanicacid 30µg 19 - 20 
Cephelexin  30µg 14 15-17 18 
Cefotaxime    30 µg 14 15-22 23 
Ciprofloxacin  5 µg 15 16-20 21 
 Fig1: Gram stain showing Staphylococcus aureus 
 
 
 
 
 
 Fig2: Beta Haemolysis on Blood agar 
        
 
 
Fig3: Staphylococcus aureus colonies on Mannitol salt 
agar 
 
  
Fig4: Slide coagulase test 
 
        
 
                          
Fig5: Tube coagulase test 
 
 
 
    
 Fig6: Antibiogram of S.aureus isolates
 
 
 
 
 
 
 
 
  
Fig7: MRSA detection using cefoxitin and oxacillin discs 
 
 
 
Fig8: Constitutive Clindamycin  resistance 
 
 
 
 
  
Fig9: Inducible clindamycin resistance 
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RESULTS 
The study was performed during the period from September 2011 
to August 2012 at department of microbiology, Coimbatore Medical 
College Hospital. This study was done to find the incidence of MRSA 
using oxacillin and cefoxitin disc diffusion methods and to compare 
inducible clindamycin resistance with constitutive resistance. 
The study included 200 staphylococcus aureus isolates from 
samples like pus, blood, sputum,vaginal swab, urine and body fluids. 
Among 200 staphylococcus aureus isolates the sample wise 
distribution was as follows. Pus constituted 175 (87.5%), urine 10 (5%), 
blood 6 (3%), sputum 4 (2%), vaginal swab 3 (1.5%)   and synovial fluid 
2 (1%), as given in Table1 and Chart1. 
The above observation shows that staphylococcus aureus was 
isolated maximally from pus Samples (87.5%) and only few were isolated 
from urine, blood, sputum, vaginal swab and other body fluids. 
The resistant and sensitivity pattern of staphylococcus aureus 
isolates to different antibiotic groups is given in Table2 and Chart 2. 
Out of the 200 staphylococcus aureus isolates100% were sensitive 
to linezolid and 99% were sensitive to vancomycin. 
77 % were sensitive to amikacin, 73%were sensitive to 
doxycycline, 69% were sensitive to cotrimoxazole, 68.5 % were sensitive 
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to cephalexin, 66.5 % were sensitive to amoxy clavulanicacid, 64 % were 
sensitive to cefotaxime, 59 % were sensitive to ciprofloxacin. 
Staphylococcus aureus strains were highly sensitive to linezolid and 
vancomycin. Moderate level sensitivity was seen in amikacin, 
doxycycline, cotrimoxazole, cephalexin, amoxy clavulanicacid, 
cefotaxime and ciprofloxacin. 
Table2 and Chart 2 lists the resistance pattern of staphylococcus 
aureus isolates. Out of the 200 isolates 100% were resistant to penicillin 
G, 33.5% were resistant to ciprofloxacin, 33.5 % were resistant to amoxy 
clavulanicacid, 27.5 % were resistant to cephalexin, 27.5% were resistant 
to cotrimoxazole, 26.5 % were resistant to cefotaxime, 24.5% were 
resistant to doxycycline, 20.5 % were resistant to amikacin and 1% were 
resistant to vancomycin. 
Staphylococcus aureus isolates were 100% resistant to penicillin 
and 100% sensitive to linezolid. Moderate level of resistance were seen to 
amikacin, ciprofloxacin, doxycycline, co-trimoxazole,  cephalexin, 
cefotaxime and amoxy clavulanicacid. Very minimal resistance was 
noted in vancomycin. 
As evident from Table 3 and Chart 3 among 200 isolates of 
staphylococcus aureus, 26% were resistant and 74 % were sensitive to 
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cefoxitin whereas 24% were found to be resistant and 76% were sensitive 
to oxacillin as determined by disc diffusion method.Cefoxitin disc 
detected higher percentage of methicillin resistant staphylococcus aureus 
by disc diffusion method. 
Among 200 staphylococcus aureus isolates74% MSSA and 26% 
MRSA were observed as given in Table 4 and Chart4. 
Age wise distribution as given in  Table  5 and Chart 5 shows out 
of 200  S.aureus isolates taken for study, 15.50%  between  1-12 years,  
9.50% between 13-20 years,  42.50%  between 21-40 years, 19.50% 
between 41-60 years and 13% more than 60 years of age. 
Out of 52 MRSA isolates 9.61% were between 1-12 years, 11.54% 
were between 13-20 years, 51.92% were between 21-40 years, 15.38% 
were between 41-60 years, and 11.54% were more than 60 years of age. 
From this it is inferred that maximum staphylococcus aureus and 
MRSA isolates were from the age group between 21-40 years followed 
by 41-60 years age. 
Among 52 MRSA isolates sex ratio was found to be 65.38 % 
Males and 34.61 % Females .This is given in Table 6 and Chart 6 
indicating predominance of MRSA among males. 
 As listed in Table 7 and Chart 7 out of 200 Staphylococcal isolates 
40 % were isolated from wound infection, 9 % from cutaneous ulcer, 8 % 
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from abscess, 7.5 % from cellulitis, 7.5 % from suppurative otitis media, 
6 % from pyoderma, 5% from urinary tract infection 4% from 
osteomyelitis, 3% from burns, 3% from septicemia, 2% from pneumonia 
1.5 % from gangrene, 1.5 % from vaginal infection 1% from necrotizing 
fascitis, and 1% from septic arthritis. 
 MRSA were isolated from 44.23 % of wound infection, 11.54 % of 
cutaneous ulcer, 9.62% of abscess, 7.69 % of cellulitis, 7.69 % of  
pyoderma , 5.77 %  of osteomyelitis, and 3.85 % of urinary tract 
infection. Burns, septicemia, gangrene, necrotizing fascitis, and 
suppurative  otitis media cases  constituted 1.92%  of MRSA  each. 
It is inferred from the above data that wound infections constituted 
higher percentage of MRSA. 
Analysis of clindamycin Resistance in 52 MRSA isolates showed 
42.30% of inducible clindamycin Resistance, 30.76 % of constitutive 
clindamycin Resistance, and 26.92% were sensitive to both erythromycin 
and clindamycin.  MS phenotype was not observed as given in Table 8 
and Chart 8. 
Above observation shows that, inducible clindamycin resistance 
was reported in a higher percentage than constitutive clindamycin 
resistance. 
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TABLE NO.1 
FREQUENCY OF STAPHYLOCOCCUS AUREUS 
ISOLATES IN   DIFFERENT SPECIMENS 
                                                                                           n-200 
 
 
 
 
 
Samples 
Total no of S.aureus 
isolates 
Percentage 
Pus 175 87.5% 
Urine 10 5% 
Blood 6 3% 
Sputum 4 2% 
Vaginal swab 3 1.5% 
Synovial fluid 2 1% 
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TABLE 2 
ANTIBIOTIC SENSITIVITY PATTERN OF  
STAPHYLOCOCCUS AUREUS 
                                                                                                 n=200 
 
 
 
Drugs Sensitive 
Intermediate 
sensitive 
Resistant 
Linezolid 200 (100%) - - 
Vancomycin 198 (99%) - 2 (1%) 
Amikacin 154 (77 %) 5 (2.5 %) 41 (20.5%) 
Doxycycline 146 (73%) 5 (2.5%) 49 (24.5% ) 
Cotrimoxazole 138 (69%) 7 (3.5%) 55  (27.5% ) 
Cephalexin 137 (68.5%) 8 (4%) 55  (27.5% ) 
Amoxy clavulanic acid 133 (66.5%) - 67 (33.5%) 
Cefotaxime 128 (64%) 19 (9.5%) 53 (26.5%) 
Ciprofloxacin 118 (59% ) 15 (7.5%) 67 (33.5%) 
penicillin G - - 200 (100 % ) 
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TABLE-3 
DETECTION OF METHICILLIN RESISTANCE BY DISC 
DIFFUSION  TEST USING OXACILLIN AND CEFOXITIN DISCS 
                                                                                     n=200 
 
TABLE 4 
PREVALENCE OF MRSA AMONG STAPHYLOCOCCUS 
AUREUS ISOLATES 
 
 
 
 
 
 
Discdiffusion test Cefoxitin(30µg) disc 
Oxacillin (1µg)  
disc 
Resistant 52 (26 %) 48 (24 %) 
Sensitive 148 (74 %) 152 (76%) 
Total isolates MRSA MSSA 
200 52 (26%) 148 (74%) 
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TABLE -5 
AGE WISE DISTRIBUTION OF MRSA 
 
TABLE.6 
GENDER DISTRIBUTION OF MRSA 
 
Age in years 
Total no of S.aureus 
isolates(200) 
MRSA(52) 
1-12 31 (15.50%) 5 (9.61%) 
13-20 19 (9.50%) 6 (11.54%) 
21-40 85 (42.50%) 27 (51.92%) 
41-60 39 (19.50%) 8 (15.38%) 
> 60 26 (13.% ) 6 (11.54%) 
Sex Total (200) MRSA (52) 
Male 120 34 (65.38 %) 
Female 80 18 (34.61%) 
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TABLE-7 
DISTRIBUTION OF MRSA AMONG VARIOUS INFECTIONS 
Diseases Total (200) MRSA (52) 
Wound infection 80 (40 %) 23 (44.23 % ) 
Cutaneous  ulcer 18 (9 %) 6 (11.54 %) 
Abscess 16 (8 %) 5 (9.62%) 
Cellulitis 15 (7.5 %) 4 (7.69 %) 
Pyoderma 12 (6 %) 4 (7.69 %) 
Osteomyelitis 8 (4%) 3 (5.77 %) 
Urinary tract infection 10 (5%) 2 (3.85 %) 
Suppurative otitis media 15 (7.5 %) 1 (1.92%) 
Burns 6 (3%) 1 (1.92%) 
Septicemia 6 (3%) 1 (1.92%) 
Gangrene 3 (1.5 %) 1 (1.92%) 
Necrotizing fascitis 2 (1%) 1 (1.92%) 
Pneumonia 4 (2%) 0 (0%) 
Vaginal infection 3 (1.5%) 0 (0%) 
Septic arthritis 2 (1%) 0 (0%) 
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Table.8: Clindamycin Resistant phenotypes of MRSA by D-test 
 
ERY- R: Erythromycin resistant. 
CLI-R : Clindamycin resistant 
CLI-S: Clindamycin sensitive 
ERY-S: Erythromycin sensitive. 
iMLS
 B-- Inducible Clindamycin resistance 
cMLS
 B- Constitutive Clindamycin resistance 
S – Phenotype: Susceptible phenotype 
MS phenotype-  Macrolide Streptogramin (type B) resistance.
Susceptibility pattern (phenotype) MRSA(52) 
Percentage 
(26%) 
ERY R, CLI-S (D -Test positive; iMLS
 B) 22 42.30% 
ERY-R, CLI-R ( cMLS
 B) 16 30.76% 
ERY-S, CLI-S (S - Phenotype ) 14 26.92% 
ERYR, CLI-S (D –Test negative;MS 
Phenotype) 
Nil 0 % 
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DISCUSSION 
MRSA is a major cause of hospital and community acquired 
infections. Clindamycin is an excellent drug to treat not only serious 
infections like sepsis, endocarditis, osteomyelitis, pneumonia, and 
staphylococcal scalded skin syndrome caused by MRSA but also MSSA. 
It is less expensive compared to newer antibiotics. 
As it can be given orally it can be used in outpatient therapy. Drugs 
like tetracyclines and fluroquinolones are not advised for treating children 
and pregnant women due to side effects. But clindamycin is a treatment 
of option in children and it can also be used in penicillin allergic 
individual1,62. 
It is very necessary to distinguish between staphylococci   having 
inducible clindamycin resistance from those with MS Phenotype.  
Because MS Phenotype in staphylococcal strains does not result in failure 
of therapy, whereas it occurs in inducible clindamycin resistance1. 
D test is a simple, reliable and significant test. Sensitivity of D test 
performed at 15mm disk spacing is 100% corelated with detection of erm 
genes by polymerase chain reaction63. 
In the present study 200 samples were processed and results were 
analysed. 
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In this study majority of the staphylococcus aureus isolates 
,(87.5%) were from  pus samples while 5%, were from urine, 2% were 
from sputum, 3%, were from blood, 1.5% were from vaginal swab and 
1% were from synovial fluid. This is supported by the study of Vidyapai 
et al 2011 who has isolated 181(76.3%) of staphylococcus aureus in pus 
samples followed by 28(11.81%) from urine, 17(7.17%) from respiratory 
specimen, 9(3.79%) from blood and 2(0.84%) from body fluids65. This 
also correlates with the study conducted by Anupurba et al 2003, in 
which, they have reported 381(69.39%) of staphylococcus aureus in pus 
samples followed by 59 (10.74%) from urine, 25(4.55%) from high 
vaginal swab, 27(4.91%) from body fluids, and sputum 23(4.18%)79. 
Lakari  Saikia  et al 2009  has reported 46.67%  of  staphylococcus 
aureus from pus and 42.86% from sputum 24. 
The present study showed multidrug resistant pattern of   
staphylococcus aureus as amikacin 20.5%, ciprofloxacin 33.5%, 
doxycycline 24.5%, cotrimoxazole 27.5%, cephelexin 27.5 % cefotaxime 
26.5 %, penicillin G 100%, vancomycin 1% and amoxy clavulanic acid 
33.5 %.The present study showed 100% sensitivity to linezolid. In 
accordance with present study, Shilpa Arora et al 2010 has reported 
antimicrobial resistance of staphylococcus aureus as amikacin(22%), 
ciprofloxacin (52.8%) , cephelexin (56.8%) and  penicillin(78.4%).  
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Staphylococcus aureus was 99.2% sensitive to linezolid and 100% 
sensitive to vancomycin49. Adebayo O Shittu et al 2006 in his study of 
227 staphylococcus aureus isolates has reported that 70 isolates (30.8%) 
were resistance to cotrimoxazole, 68 isolates (30%) were resistant to 
tetracycline54. Vidhani S. et al 2001 has documented 87% of 
staphylococcus aureus isolates resistant to amoxy clavulanic acid, 100% 
resistant to penicillin and 78.5% resistant to cefotaxime80. 
The present study showed 26% of MRSA among 200 
staphylococcus aureus isolates. The above data correlates with the result 
of Vidyapai et al 2011 who has documented 29.1% MRSA65.    This is in 
accordance with study of Gupta V et al 2009 who has documented 25% 
of MRSA among 200 staphylococcus aureus isolates66. Pal N 2010 has 
documented 31.60% of MRSA56 , Oommen S.K 2010 has reported 
28.7% of MRSA81. Jadhav Savita Vivek et al 2011 has reported 32.5% 
of MRSA82.In contrary Anupurba S et al 2003 has reported 54.8% of 
MRSA in their study79. 
Presence of predisposing factors such as prolonged hospital stay 
and antibiotic intake as evidenced by Mathanraj etal  may be the reason 
for high MRSA report  among inpatients25. Invasive procedures and use 
of resistant antibiotics results in bacteremia by MRSA7. 
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By disc diffusion method the present study showed 26% of MRSA 
using cefoxitin disc,and 24% of MRSA by oxacillin disc.                                   
Similarly Shilpa Arora et al 2010 have detected 46% of MRSA by 
cefoxitin disc diffusion method and 40.4% of MRSA by oxacillin disc 
diffusion method .This shows that cefoxitin is superior to oxacillin in 
detecting MRSA 49. 
Maximum number of MRSA isolates in this study were among 21-
40 years (51.92%) followed by 41-60 years (15.38%).                              
Similarly Gayathri Naik  et al 2011 studies report maximum number of 
patients belong to the to age group of 21- 30 years. the males being 
25.9% and females 22.2%83. 
In the Present study among MRSA isolates 65.38 % were males 
and 34.61% were females. In the study by Shaileshkumar et al 2011,59 
% of males and 41 % of females infected with MRSA has been reported 
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. Waness A in 2010 has mentioned that MRSA infections have male 
predilection7. This may be attributed to the increased mobility of the male 
population. 
In this study highest MRSA is reported in wound infections 
(44.23%). Orthopaedic patients operated for open fractures showed 
highest incidence of wound infection followed by surgery and obstetrics 
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and gynaecology. Shilpa Arora et al 2010isolated 54.8% of MRSA from 
surgical units, and 27.8% from orthopaedic wards 49 . Shaileshkumar et 
al isolated MRSA, commonly from surgical site infection, orthopaedic 
infection and bone fractures 61. 
Mathanraj et al isolated highest number of MRSA in orthopaedic 
ward and dermatology ward. Patients with extensive skin lesions are 
heavy shedders of MRSA .So the rate was high in orthopaedic ward and 
dermatology ward. It was due to big surface area of denuded skin with 
large inoculam of organism that can easily be transmitted to other patients 
via hands of health care workers25. 
The common complications following all operative procedure is 
surgical site infections. Pre operative care, the theatre sterility, 
postoperative care, overcrowding, and the type of surgery are some of the 
factors which determine the surgical site infections. Contamination from 
the external environment is the most probable reason for the wound 
infection (Gayathri Naik et al 2011) 83. In a study at AIMS New Delhi 
Arti Tyagi et al 2008 has reported high intensity of MRSA in ICU and 
surgical units due to greatest antibiotic usage 84.  The increased incidence 
of MRSA in wound infection is due to the production of PVL by MRSA 
which is associated with tissue necrosis, leucocyte destruction20. 
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Clumping factor, coagulase and hyaluronidase helps in invasion and 
existence in tissues20. Higher rate of MRSA carriage has been reported in 
the surgical, orthopaedic, obstetric and gynecological wards 25,61,84. This 
might be attributed to prolonged hospital stay due to fractures and 
operative procedures.  J B Sarma, G.U.Ahmed in 2010 reported that 
surgery is a risk factor as prophylactically used antibiotics is irrationally 
continued for several days which may account for the acquisition of 
MRSA 85. 
Present study showed higher rate (42.30%), of inducible 
clindamycin resistance than constitutive clindamycin resistance (30.76%), 
among MRSA. Similarly Ciraj AM et al 2009 has reported 38% of 
inducible clindamycin resistance and 15.3% of constitutive clindamycin  
resistance86.  Likewise Bidya Shrestha et al 2009 has reported higher 
percentage (44.4%) of inducible clindamycin resistance than constitutive 
clindamycin resistance (39.7%)87. Angel MR et al 2008, 60 and Sureerat 
Chelae 200988 have reported 37%, 35.9% of inducible clindamycin 
resistance respectively.  Vasanthi R et al has reported17.3% of inducible 
clindamycin resistance and 9.6% of constitutive clindamycin   resistance 
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. Deotale et al 2010 have reported   14.5% of inducible clindamycin 
resistance and 3.6% of constitutive clindamycin resistance55. Jadhav 
Savita Vivek et al 2011 have reported 24.8% of inducible clindamycin 
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resistance and 8.2% of constitutive clindamycin resistance82. Kavitha 
prabhu et al 2011 have documented 20% of inducible clindamycin 
resistance and 16.6% of constitutive clindamycin resistance 5. 
Ajanta GS et al have documented high rate (74%) of inducible 
clindamycin resistance57. Amruthkishan Upadhya et al 2011 have 
documented high rate (61.08%) of inducible clindamycin resistance in 
their study 89. Shailesh kumar et al 2012 reported 75% MRSA isolates 
found to be iMLSB. The low constitutive resistance was that the drug is 
not commonly used and so there is less selection of resistant strains 61 . 
Contrasting results were published by Gupta V et al 2009 who has 
documented high rate of constitutive clindamycin resistance (46%) than 
inducible clindamycin resistance (20%)66. Hwan Sublim 2006 has 
reported high rate of 78% in constitutive clindamycin resistance and 19% 
inducible clindamycin resistance (20%)62. Mohamad 2007 has reported 
47.6% constitutive clindamycin resistance and 22.6% inducible 
clindamycin resistance16.  Angel MR et al 2008 has not reported any 
constitutive clindamycin resistance in their study60. 
The present study haven’t found out any MS Phenotype.Likewise 
Sureerat Chelae 2009 has reported only 1.1 % of MS Phenotype 88. In 
contrary 7.97% of MS Phenotype has been reported by Amruthkishan 
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Upadhya et al 2011 89. Clindamycin susceptible rates are higher than 
erythromycin regardless of methicillin susceptibility. The difference in 
percentage of iMLSB resistance and constitutive resistance is explained 
by the difference in bacterial susceptibility in various geographical areas 
and varied antibiotic prescription by the clinicians64. 
Staphylococcus aureus has emerged as a major cause of 
nosocomial infections for quite some time. Clindamycin is a very useful 
drug in treating skin and soft tissue infections. It can be used in penicillin 
allergic individual.  It is a promising therapeutic option in the era of drug 
resistance. The costly antibiotics like vancomycin can be reserved for 
severe illness.The erythromycin resistant Staphylococcal isolates will be 
misidentified as clindamycin sensitive if D test is not performed. To 
avoid prescribing clindamycin to those who exhibit inducible 
clindamycin resistance, D test must be done routinely. 
Giving false report that patient is infected with MRSA will lead to 
fatal consequences due to inadequate therapy, whereas wrongly labelling 
the patient infected with MSSA as MRSA will lead to unwanted usage of 
costly drugs like  vancomycin. 
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SUMMARY 
• Majority of staphylococcus aureus were isolated from pus samples 
(87.5%). 
• Staphylococcus aureus was highly sensitive to linezolid (100%) 
and vancomycin (99%). 
• Antimicrobial sensitivity results showed that staphylococcus 
aureus were 100% resistant to penicillin. 
• Moderate level of antimicrobial resistance were seen to amikacin 
(20.5%), ciprofloxacin (33.5%), doxycycline (24.5%), 
cotrimoxazole (27.5%) , cephelexin( 27.5 %), cefotaxime (26.5 %), 
and amoxy clavulanic acid (33.5 %). 
• Cefoxitin disc detected higher percentage (26%) of MRSA by disc 
diffusion method on comparison to oxacillin disc diffusion method 
which detected (24%) of MRSA. 
• Sex distribution revealed predominance of males (65.38%) over 
females (34.61%) among the 200 staphylococcus aureus isolates. 
• Among 52 MRSA maximum number of isolates were from the age 
group between 21-40 years (51.92%) followed by 41-60 years 
(15.38%).   
• Wound infections constituted higher percentage (44.23%) of 
MRSA followed by cutaneous ulcer (11.54%) and abscess( 9.62%).     
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• MS Phenotype was not reported in the present study.Erythromycin 
and clindamycin sensitivity was noted in 26.92 %.Higher 
percentage of inducible clindamycin resistance (42.30%)was  
reported in MRSA than constitutive clindamycin 
resistance(30.76% ). 
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CONCLUSION 
Among the 200 staphylococcus aureus isolates 26% were 
methicillin resistant.  Analysis of clindamycin resistance in 52 MRSA 
isolates showed 42.30% of inducible clindamycin resistance. These 
isolates are seemed to be susceptible to clindamycin in vitro but, 
treatment failure occurs when this drug is instituted as invivo therapy.  
MRSA infection in surgical site is commonly noted. Multidrug resistance 
to commonly used drugs like ciprofloxacin, amikacin, doxycycline and 
cotrimoxazole are to be noted with concern. 
Staphylococcus aureus is a leading cause of hospital acquired 
infections including pneumonia, endocarditis, bacteremia, and surgical 
wound infections. The problem is exacerbated by the ability of the MRSA 
to colonize the individuals years together and infect them frequently. 
The increase in staphylococcus aureus infections is a outcome of 
organism's ability to adapt to a changing environment and its capability to 
spread. MRSA is a threat not only to immunocompromised   individuals, 
but also to general public. Moreover emergence of drug-resistance among 
MRSA is now a major concern. 
So detection of methicillin resistance in staphylococcus aureus is  
very important for treating patients and to prevent its spread.  
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Drugs like clindamycin are needed to stem the severe 
consequences of MRSA. Use of clindamycin avoids costly, intravenous 
glycopeptides for treating MRSA. Clindamycin is a treatment of option in 
children. It can be used in penicillin allergic individual. It has good oral 
bioavailability. So it can be used by clinicians as outpatient therapy as 
well as to switchover after intravenous antibiotics in hospitalized patients. 
The pattern of clindamycin resistance to MRSA varies in different 
regions. When clindamycin is considered for therapy, the kind of 
resistance (inducible or constitutive clindamycin resistance) which exists 
to be detected. 
‘D test’ is absolutely necessary in microbiology laboratories. This 
is because it avoids misinterpretation of clindamycin resistance by clearly 
delineating inducible clindamycin resistance from constitutive 
clindamycin resistance. Moreover it is simple, cost effective, and reliable. 
So ‘D’ test is suggested along with routine antibiotic susceptibility 
testing to detect inducible clindamycin resistance and thus avoid 
treatment failure. Hence this study was done. 
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 PROFORMA 
Name:                                                                        Date: 
Age:                                                                                 IP /OP No: 
Sex:                                                                                   Ward: 
Address: 
Diagnosis of the patient: 
Specimen: 
Laboratory analysis: 
Microscopy: 
Culture: 
Biochemical reactions: 
Antibiomicrobial sensitivity: 
Interpretation: 
Details of Investigator: 
Name:                                                                                    Signature 
                                              
 
 
 
 PROTOCOL 
Study Design – Prospective Cohort study 
Study Materials – 200 Staphylococcus aureus isolates 
Methodology- 
                       All Clinical samples 
 
Direct smear study       culture isolation 
Gram stain  Biochemical identification 
                                             Staphylococcus aureus 
 
       Antibiotic sensitivity test 
       
  MRSA 
         
 
   ‘D’ Test 
 (Disc approximation test -Erythromycin,clindamycin disc ) 
 
 
 
Erythromycin resistant     Erythromycin resistant     Erythromycin resistant    Erythromycin  sensitive 
Clindamycin sensitive      Clindamycin sensitive           Clindamycin resistant     Clindamycin sensitive  
‘D’ Test positive         ‘D’ Test negative 
 
Inducible Clindamycin    MS phenotype       Constitutive resistance      No resistance  
resistance  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 MASTER CHART 
 S.NO AGE SEX WARD DIAGNOSIS SAMPLE Type of SA 
CD Susceptibility in 
MRSA 
DRUG -S DRUG-IS DRUG -R IR     CR      E,CD-S 
1 26 F OG WOUND INFECTION 
PUS MRSA 
 
- CR - LZ,VAN,AK,CIP,DO, COT 
- P, AMC, 
CN,CTX, 
 
2 3 M/CH SURGERY BURNS PUS MSSA - - - AMC,CTX, AK  LZ,VAN,DO,COT 
- P, CN,CIP      
3 61 M SURGERY FOURNIERS GANGRENE PUS MSSA - - - 
LZ,VAN,AK,CIP,DO, 
COT ,CN,CTX,AMC 
- P 
4 14 M SURGERY ABSCESS PUS MSSA - - - LZ,VAN,AK,CIP,DO, COT ,CN,CTX,AMC 
- P 
5 38 M 
ORTHO 
 
WOUND 
INFECTION 
PUS MRSA 
 
- - 
E,CD-
S 
 
LZ,VAN,AK, 
DO,COT ,CN, CTX, 
- P,AMC, CIP 
6 34 F OG WOUND INFECTION PUS MSSA - - - 
LZ,VAN,AK,CIP,DO, 
CN,CTX,AMC 
- P,COT 
7 27 M MEDICINE FURUNCLE PUS MSSA - - - LZ,VAN,AK,CIP,DO, COT ,CN,CTX,AMC 
- P 
8 34 M ORTHO WOUND INFECTION PUS MSSA - - - 
LZ,VAN,AK,CIP,DO, 
COT ,CN,CTX,AMC 
- P 
9 25 M SURGERY ABSCESS PUS MSSA - - - 
LZ,VAN,AK,CIP,DO,   
COT ,CN,CTX,AMC 
- P 
10 5 M/CH ENT ASOM PUS MSSA - - - 
LZ,VAN,AK,CIP,DO,  
COT ,CN,CTX,AMC 
- P 
11 50 M ORTH0 WOUND INFECTION 
PUS MRSA IR - - LZ,VAN COT P, AMC,AK,CIP, CN,CTX,DO 
12 23 F OG WOUND INFECTION PUS MSSA - - - 
LZ,VAN,AK,CIP,DO, 
COT ,CN,CTX,AMC - P 
13 44 F SURGERY CELLULITIS PUS MSSA - - - LZ,VAN,AK,CIP,DO, COT ,CN,CTX,AMC - P 
 14 29 M SURGERY NECROTIZING FASCITIS 
PUS MRSA IR - - LZ,VAN - 
P, AMC,AK,CIP, 
CN,CTX,DO,CO
T 
15 37 F OG WOUND INFECTION PUS MSSA - - - 
LZ,VAN,AK,CIP,DO, 
COT ,CN,CTX,AMC - P 
16 35 M ORTH0 WOUND INFECTION 
PUS MRSA IR - - LZ,VAN - 
P, AMC, AK,CIP, 
CN,CTX,DO,CO
T 
17 25 M ORTH0 WOUND INFECTION PUS MSSA - - - LZ,VAN,CIP,COT,CN AK P, AMC DO,CTX 
18 45 M SURGERY CELLULITIS PUS MRSA - - E,CD-S 
LZ,VAN,AK,CIP,DO, 
CN,COT - P,AMC,CTX 
19 35 M SURGERY WOUND INFECTION 
PUS MRSA IR - - LZ,VAN,AK DO, CTX, P,AMC,COT, CIP,CN , 
20 23 F SURGERY WOUND INFECTION PUS MSSA - - - 
LZ,VAN,AK,CIP,DO, 
COT ,CN,CTX,AMC - P 
21 62 M SURGERY ABSCESS PUS MSSA - - - LZ,VAN,AK,CIP,DO, COT ,CN,CTX,AMC - P 
22 58 M ORTHO WOUND INFECTION PUS 
MSSA 
 
- - - 
AK, DO, 
CN,CTX, VAN,LZ ,CIP P,AMC,COT 
23 20 F ORTHO OSTEOMYELITIS 
PUS MSSA - - - LZ,VAN,AK,CIP,DO, COT ,CN,CTX,AMC - P 
24 4 M/CH SURGERY WOUND INFECTION 
PUS MSSA - - - LZ,VAN,AK,DO,COT CN,CTX,AMC CIP P, 
25 45 F ORTHO WOUND INFECTION 
PUS MSSA - - - LZ,VAN,AK,DO,COT CN,CTX,AMC CIP P 
26 36 F SURGERY CELLULITIS PUS MSSA - - - LZ,VAN,AK,CIP,DO, COT ,CN,CTX,AMC, - P 
27 80 M ORTHO WOUND INFECTION 
PUS MRSA - CR - LZ,VAN,AK,CIP AMC, CTX - 
P, COT, 
DO,CN, 
 28 28 M SURGERY ULCER LEG PUS MSSA - - 
E,CD-
S 
 
LZ,VAN,AK,CIP,DO, 
COT ,CN,CTX,AMC - P 
29 30 F NEPHROLOGY 
ULCER RIGHT 
ARM 
PUS MRSA - CR - LZ, - 
P,AMC,CN,AK 
CIP, VAN,CTX, 
DO, COT 
30 2 FCH PAEDIATRICS ASOM 
PUS MSSA - - - LZ,VAN,AK,CIP,DO, COT ,CN,CTX,AMC - P 
31 45 F SURGERY GANGRENE PUS MSSA - - - LZ,VAN,AK,DO,COT CN, AMC ,CIP,CTX P 
32 30 F MEDICINE 
URINARY 
TRACT 
INFECTION 
URINE MRSA - CR - LZ,VAN,CN, CTX P,AMC, AK,CIP  DO,COT 
33 32 F MEDICINE 
URINARY 
TRACT 
INFECTION 
URINE MSSA - - - LZ,VAN,AK,CIP,DO, COT ,CN,CTX,AMC - P 
34 29 F OG WOUND INFECTION 
PUS MSSA - - - LZ,VAN,AK,DO,COT CN,CTX,AMC - P,CIP 
35 25 F MEDICINE 
URINARY 
TRACT 
INFECTION 
URINE MSSA - - - LZ,VAN,AK,DO,CN, CTX,AMC - P,CIP,COT 
36 10 days FCH 
PAEDIATR
ICS 
TRANSIENT 
NEONATAL 
PUSTULOSIS 
PUS MRSA - CR - LZ,VAN,AK,CIP,DO, 
 
CTX,CN 
P, AMC, 
COT, 
 
37 45 F ORTHO WOUND INFECTION PUS MRSA - - 
E,CD-
S 
 
LZ, AK, DO, 
COT, CN 
CIP, 
CTX P, AMC VAN, 
38 15 days FCH SURGERY ABSCESS PUS MRSA - - 
E,CD-
S 
 
LZ,VAN,AK,DO, 
COT CTX 
P,  AMC, 
CN,  CIP 
39 33 M SURGERY WOUND INFECTION PUS 
MRSA 
CX-R 
OX-S 
IR - - LZ,VAN - P,AMC,CN,CTX,AK CIP, DO,COT 
40 80 M SURGERY ULCER FOOT PUS MRSA - CR - CTX, LZ ,VAN, - P,AMC,CN,AK, DO,  CIP,  COT 
41 40 M SURGERY 
ORAL 
CARCINOMA 
WITH ULCER 
PUS MRSA 
 
- CR - LZ,VAN,AK,CIP,COT, CTX,CN - P, AMC, DO, 
 42 25 M ENT ASOM PUS MSSA - - - LZ,VAN,AK,DO,COT CN,CTX,AMC - P ,CIP 
43 52 M ORTHO WOUND INFECTION 
PUS MSSA - - - LZ,VAN,AK,DO CN,CTX,AMC CIP P , COT 
44 11 FCH SURGERY ULCER    SCALP PUS MSSA 
 
- - - COT, LZ, VAN  
CTX, CN,DO, 
AK, 
CIP,P,AMC 
45 50 M SURGERY WOUND INFECTION 
PUS MSSA 
 
- - - VAN,DO LZ  CTX,CN,COT, P, AMC,CIP,AK, 
46 35 M SURGERY ULCER LEFT LEG 
PUS MSSA - - - LZ,VAN,COT,CN,CTX AK,CIP,DO P,AMC, 
47 87 M ENT 
SUPPURATIVE 
OTITIS 
EXTERNA 
 
PUS MSSA - - - LZ,VAN, CIP, COT CN,AMC AK,DO P,CTX 
48 62 M ORTHO OSTEOMYELITIS 
PUS MSSA 
- - - 
LZ,VAN,AK,CIP,DO, 
COT ,CN,CTX,AMC  P 
49 80 F ORTHO WOUND INFECTION 
PUS MSSA 
- - - LZ,VAN,AK,AMC CTX P, DO, COT, CIP, CN 
50 21 F OG WOUND INFECTION 
PUS MSSA 
- - - LZ,VAN,AK ,COT CTX, CN P,AMC,CIP, DO 
51 50 M ORTHO 
 
WOUND 
INFECTION 
PUS MSSA - - - LZ,VAN,AK COT 
 
P, AMC, 
CN,CTX CIP, DO 
 
52 50 M ORTHO WOUND INFECTION PUS MRSA  CR - LZ,VAN, DO 
CIP, 
COT,CTX P, AMC, CN,AK 
53 25 F ORTHO WOUND INFECTION PUS MRSA IR - - LZ,VAN  
P,CN,CTX,AMC,
AK,CIP,COT ,DO 
54 15 M MEDICINE 
URINARY 
TRACT 
INFECTION 
URINE MRSA IR - - LZ,VAN, DO,COT  
P, AMC 
,CN,CTX, 
AK,CIP 
55 23 M ORTHO WOUND INFECTION PUS MSSA - - - 
LZ,VAN,AK,CIP,DO, 
CN,AMC CTX,COT P 
56 28/365 FCH 
PAEDIATR
ICS SEPTICEMIA BLOOD MSSA - - - 
LZ,VAN,AK,CIP,DO,CO
T ,CN,CTX,AMC  P 
 57 50 F SURGERY BURNS PUS MSSA - - - LZ,VAN,AK,CIP,DO,COT ,CN,CTX,AMC  P 
58 32 M MEDICINE WOUND INFECTION 
PUS MSSA - - - LZ,VAN,AK,CIP,DO,COT ,CN,CTX,AMC  P 
59 29 F MEDICINE 
URINARY 
TRACT 
INFECTION 
URINE MSSA - - - LZ,VAN,AK,CIP,DO,COT ,CN,CTX,AMC  P 
60 25 M SURGERY WOUND INFECTION PUS MSSA - - - 
LZ,VAN,AK,CIP,DO,CO
T ,CN,CTX,AMC  P 
61 34 F SURGERY WOUND INFECTION 
PUS MSSA - - - LZ,VAN,AK,CIP,DO,COT ,CN,CTX,AMC  P 
62 50 M MEDICINE CELLULITIS 
 
PUS MSSA - - - LZ,VAN,AK,CIP,DO,COT ,CN,CTX,AMC  P 
63 20 F ORTHO WOUND INFECTION 
PUS MSSA - - - LZ,VAN,AK,DO CN,CTX,AMC COT,CIP P 
64 
 
35 F ORTHO WOUND INFECTION 
PUS MSSA - - - LZ,VAN,AK,CIP,DO,COT ,CN,CTX,AMC  P 
65 20 M ORTHO PELVIC  ABSCESS PUS MRSA IR - - LZ,VAN  
P, 
AMC,CN,CTX, 
AK,CIP ,DO,COT 
66 9 MCH SURGERY 
URINARY 
TRACT 
INFECTION 
URINE MSSA - - - LZ,VAN, DO,COT,AK CTX,CIP CN P, AMC 
67 18 M ORTHO WOUND INFECTION PUS MRSA IR - - LZ,VAN  
P, AMC 
,CN,CTX, 
AK,CIP,DO,COT 
68 19 M 
 
SURGERY ULCER PUS MRSA - CR - LZ,VAN  
P, AMC 
CN,CTX, 
AK,CIP,DO,COT 
69 51 M SURGERY CELLULITIS PUS MSSA - - - LZ,VAN,AK,CIP,DO, COT ,CN,CTX,AMC  P 
70 38 M ORTHO WOUND INFECTION PUS MRSA - CR - LZ,VAN,AK, CTX ,CN 
P, AMC, 
CIP,DO,COT, 
71 31 M ORTHO WOUND INFECTION PUS MRSA - CR - LZ,VAN  
P, 
AMC,CN,CTX,  
AK ,CIP, 
DO,COT 
 72 22 F OG WOUND INFECTION 
PUS MSSA - - - LZ,VAN,DO,AMC 
 
CTX, CN P,CIP,AK,COT, 
73 63 M MEDICINE FURUNCLE PUS MSSA - - - LZ,VAN,CN,CTX,AMC 
AK , 
DO 
,COT,CIP 
P 
74 9 FCH ORTHO WOUND INFECTION 
PUS MSSA - - - LZ,VAN,AK,CIP,DO, COT ,CN,CTX,AMC  P 
75 25 F OG WOUND INFECTION 
PUS MSSA - - - LZ,VAN,AK, CN,AMC 
DO 
COT,CIP,C
TX, 
P, 
76 13 F SURGERY WOUND INFECTION 
PUS MSSA - - - LZ,VAN,AK,CIP,DO, COT ,CN,CTX,AMC  P 
77 40 M SURGERY CELLULITIS PUS MSSA - - - LZ,VAN,AK,CIP,DO, COT ,CN,CTX,AMC  P 
78 4YR MCH SURGERY WOUND INFECTION 
PUS MSSA - - - LZ,VAN,AK,CIP,DO, COT ,CN,CTX,AMC  P 
79 15 F ORTHO SEPTIC ARTHRITIS 
SYNOVIA
L FLUID MSSA - - - 
LZ,VAN,AK,CIP,DO, 
COT ,CN,CTX,AMC  P 
80 8 MCH ENT TONSILLAR ABSCESS 
PUS MSSA - - - LZ,VAN,AK,CIP,DO, COT ,CN,CTX,AMC  P 
81 46 M ORTHO WOUND INFECTION 
PUS MSSA - - - LZ,VAN,AK,CIP,DO, COT ,CN,CTX,AMC  P 
82 22 F OG WOUND INFECTION 
PUS MSSA - - - 
LZ,VAN,AK,CIP,DO, 
COT ,CN,CTX,AMC  P 
83 20 F ORTHO 
STUMP ULCER 
WITH WOUND 
INFECTION 
PUS MSSA - - - 
LZ,VAN,AK,CIP,DO, 
COT ,CN,CTX,AMC  P 
84 75 F SURGERY ABSCESS PUS MSSA - - - 
LZ,VAN,AK,CIP,DO,CO
T ,CN,CTX,AMC  P 
85 21 F ENT CSOM PUS MSSA - - - LZ,VAN,AK,CIP,DO,COT,CN,CTX,AMC  P 
86 12 F SURGERY BURNS PUS MSSA - - - 
LZ,VAN,AK,CIP,DO,CO
T, CN,CTX,AMC  P 
 87 40 F SURGERY CELLULITIS PUS MSSA - - - 
LZ,VAN,AK,CIP,DO,CO
T, CN,CTX,AMC  P 
88 24 F SKIN FURUNCLE PUS 
MRSA 
CX-R 
OX-S 
IR - - LZ,VAN  
P, AMC, 
CN,CTX 
AK,CIP,DO,COT 
89 50 M SURGERY ABSCESS  LEFT THIGH PUS MSSA - - - 
LZ,VAN,AK,CIP,DO,CO
T, CN,CTX,AMC  P 
90 15 F MEDICINE VAGINITIS VAGINAL SWAB MSSA - - - 
LZ,VAN,AK,CIP,DO,CO
T, CN,CTX,AMC  P 
91 64 M SURGERY ULCER FOOT  MSSA - - - 
LZ,VAN,AK,CIP,DO,CO
T, CN,CTX,AMC  P 
92 47 M ORTHO WOUND INFECTION PUS MSSA - - - 
LZ,VAN,AK,CIP,DO,CO
T, CN,CTX,AMC  P 
93 9 FCH SURGERY WOUND INFECTION PUS MSSA - - - 
LZ,VAN,AK,CIP,DO,CO
T, CN,CTX,AMC  P 
94 70 M MEDICINE PNEUMONIA SPUTUM MSSA - - - 
LZ,VAN,AK,CIP,DO,CO
T, CN,CTX,AMC  P 
95 2 FCH PAEDIATRICS IMPETIGO PUS MSSA - - - 
LZ,VAN,AK,CIP,DO,CO
T, CN,CTX,AMC  P 
96 24 F ORTHO WOUND INFECTION PUS MRSA IR - - LZ,VAN  
P,CN,CTX,AMC,
AK,CIP ,DO,COT 
97 55 F OG WOUND INFECTION 
PUS MSSA - - - LZ,VAN,AK,CIP,DO,COT, CN,CTX,AMC  P 
98 43 M ORTHO WOUND INFECTION 
PUS MSSA - - - LZ,VAN,AK,CIP,DO,COT, CN,CTX,AMC  P 
99 17 M SURGERY GLUTEAL ABSCESS 
PUS MSSA - - - LZ,VAN,AK,CIP,DO,COT, CN,CTX,AMC  P 
100 39 M MEDICINE PNEUMONIA SPUTUM MSSA - - - 
LZ,VAN,AK,CIP,DO,CO
T, CN,CTX,AMC  P 
 101 45 F SKIN FURUNCLE PUS MSSA - - - 
LZ,VAN,AK,CIP,DO,CO
T, CN,CTX,AMC  p 
102 1 MCH SURGERY MILIARY PUSTULOSIS PUS 
MSSA 
- - - 
LZ,VAN,AK,CIP,DO,CO
T, CN,CTX,AMC  p 
103 12 M ENT CSOM PUS MSSA - - - LZ,VAN,AK,CIP,DO,COT, CN,CTX,AMC  p 
104 25 F OG VAGINITIS 
HIGH 
VAGINAL 
SWAB 
MSSA 
- - - 
LZ,VAN,AK,CIP,DO,CO
T, CN,CTX,AMC  p 
105 65 M SURGERY WOUND INFECTION PUS 
MSSA 
- - - 
LZ,VAN,CIP,DO,COT, 
CN,CTX,AMC  P,AK 
106 12 MCH PLASTIC SURGERY BURNS PUS 
MSSA 
- - - 
LZ,VAN,AK,CIP,DO,CO
T, CN,CTX,AMC  p 
107 32 M SKIN TROPHIC ULCER PUS 
MSSA 
- - - 
LZ,VAN,AK,CIP,DO,CO
T, CN,CTX,AMC  p 
108 13 M ENT ASOM AURAL SWAB 
MSSA 
- - - 
LZ,VAN,AK,CIP,DO,CO
T, CN,CTX,AMC  p 
109 28 F ORTHO 
OSTEOMYELITI
S BOTH 
CALCANEUM 
PUS MRSA IR - - LZ,VAN,AK COT P,AMC, CN,  CTX CIP,DO, 
110 35 F SURGERY CELLULITIS PUS MRSA - - 
E,CD-
S 
 
LZ,VAN,AK,CIP,DO,CO
T,  
P,AMC, CN, 
CTX 
111 27 M ORTHO WOUND INFECTION PUS MRSA IR - - LZ,VAN CN, CTX, 
P,AMC, DO , 
COT AK,  CIP, 
112 19 M NEUROSURGERY BEDSORES PUS 
MSSA 
- - - 
LZ,VAN,AK,DO,COT, 
CN,CTX,AMC  P,CIP 
113 33 M ORTHO WOUND INFECTION PUS 
MSSA 
- - - 
LZ,VAN,AK,CIP,DO,CO
T, CN,CTX,AMC  P 
114 60 F SURGERY DIABETIC ULCER PUS 
MRSA 
 
- CR - LZ,VAN,AK,COT CTX P,AMC,CIP,DO, CN, 
115 8 FCH PAEDIATRICS 
SLE  WITH 
SKIN ULCERS PUS MSSA - - - 
LZ,VAN,DO,COT, 
CN,CTX,AMC CIP P, ,AK 
 116 45 M SURGERY WOUND GAPING 
PUS MSSA - - - LZ,VAN,AK,CIP,DO,  COT  
P, ,AMC,CN, 
CTX 
117 20 F MEDICINE FURUNCLE PUS 
MRSA 
CX-R 
OX-S 
- - 
E,CD-
S 
 
LZ,VAN,AK,CIP,DO,CO
T CTX P,AMC,CN, 
118 32 M ORTHO OSTEOMYELITIS 
PUS MSSA - - - LZ,VAN,AK,DO, CN,CTX,AMC  P,CIP,COT 
119 21day
s 
MCH SURGERY WOUND INFECTION 
PUS MRSA 
 
- CR - LZ,VAN,DO, CIP P,AMC,AK,COT,CN,CTX, 
120 38 M ORTHO OSTEOMYELITIS 
PUS MRSA 
 
- CR - VAN,LZ  
P,AMC,AK,COT,
CN,CTX,CIP, 
DO, 
121 31 M ORTHO OSTEOMYELITIS 
PUS MRSA 
 
IR  - VAN,LZ  
P,AMC,AK, CIP , 
DO,COT, 
CN,CTX, 
122 37 M ORTHO PERITONITIS,ABSCESS 
PUS MRSA 
 
IR  - AK, VAN,LZ  P,AMC,COT,CN, CTX,CIP,DO, 
123 71 M ORTHO SEPTIC ARTHRITIS 
SYNOVIA
L FLUID MSSA - - - 
AMC,AK, DO, CN, 
VAN,LZ  P,CIP,COT,CTX 
124 3months FCH 
PAEDIATR
ICS ABSCESS 
PUS MRSA 
 
IR - - LZ, CIP,DO VAN CN,CTX P,AMC,AK,COT, 
, 
125 62 M SKIN PYODERMA PUS MRSA 
 
IR - - LZ ,VAN, AK 
P,AMC, 
,CIP,COT, DO, 
CN,CTX, 
126 21 M ORTHO WOUND INFECTION 
PUS MRSA 
 
IR - - LZ,VAN,COT  
P,AMC,AK, CIP, 
DO CN,CTX, 
 
127 39 M ORTHO OSTEOMYELITIS 
PUS MSSA - - - LZ,VAN,AK,CIP,DO,COT, CN, AMC  P,CTX 
128 61 M SURGERY ULCER FOOT PUS MSSA - - - LZ,VAN,AK,CIP,DO,COT, CN,CTX,AMC  P 
129 24 F OG WOUND INFECTION PUS MSSA IR   
LZ,VAN,AK,CIP, 
DO, CN, 
CTX,AMC 
 P,COT 
130 24 F OG WOUND INFECTION PUS MSSA    
LZ,VAN,CIP,COT, 
CN,CTX,AMC  P,AK,DO 
 131 56 M MEDICINE PNEUMONIA SPUTUM MSSA    LZ,VAN,AK,CIP,DO,COT, CN,CTX,AMC  P 
132 38 M SURGERY GLUTEAL ABSCESS PUS MSSA    
LZ,VAN,AK,COT, 
CN,CTX,AMC  P,DO,CIP 
133 14 F ORTHO 
POST 
CELLULITIS 
ULCER 
PUS MSSA    LZ,VAN,AK,CIP,DO,COT, CN,CTX,AMC  P 
134 68 M ORTHO WOUND INFECTION PUS MSSA    
LZ,VAN,AK, 
DO,CN,CTX, COT,  P,  AMC ,CIP, 
135 13 M ORTHO WOUND INFECTION PUS MSSA    
LZ,VAN,AK,DO,COT, 
AMC  P,CN,CTX,CIP 
136 52 M SURGERY CELLULITIS PUS MSSA    LZ,VAN,AK,CIP,DO,COT, CN,CTX,AMC  P 
137 27 F OG WOUND INFECTION PUS MSSA    
LZ,VAN,AK, 
CN,CTX,AMC  P ,DO,CIP,COT 
138 40 M ORTHO WOUND INFECTION PUS MSSA    
LZ,VAN,AK,CIP,DO,CO
T, CN,CTX,AMC  P 
139 50 F MEDICINE BEDSORE PUS MSSA    LZ,VAN,AK,CIP,DO, COT, CN,CTX,AMC  P 
140 53 M ENT CSOM PUS MSSA    LZ,VAN,AK,CIP,DO, COT, CN,CTX,AMC  P 
141 50 F ORTHO WOUND INFECTION PUS MSSA    LZ,VAN,AK,CIP,DO  
P, AMC , 
CN,CTX, 
COT, 
142 58 M SKIN PYODERMA PUS MSSA    LZ,VAN,AK,CIP,DO, COT, CN,CTX,AMC  P 
143 55 M ORTHO OSTEOMYELITIS PUS MSSA    
LZ,VAN,AK,COT, 
CN,CTX,AMC  P, DO,CIP 
144 60 F MEDICINE ULCER FOOT PUS MSSA    LZ,VAN,AK,CIP,DO, COT, CN,CTX,AMC  P 
145 23 F MEDICINE PYODERMA PUS MSSA    LZ,VAN,CIP, CN,CTX,AMC  P,AK,DO ,COT 
146 36 M ORTHO WOUND INFECTION PUS MSSA    
LZ,VAN,AK,CIP,DO, 
COT, CN,CTX,AMC  P 
 147 27 M ORTHO WOUND INFECTION PUS MSSA    
LZ,VAN,AK,CIP,DO, 
COT, CN,CTX,AMC  P 
148 37 M SURGERY ABSCESS PUS MSSA    LZ,VAN,AK,CIP,DO, COT, CN,CTX,AMC  P 
149 40 F OG WOUND INFECTION PUS 
MRSA 
OX-S, 
CX-R 
IR   LZ,VAN,AK,DO, 
 
CIP P,AMC,CN,CTX COT, 
150 23 F ENT CSOM PUS MSSA    LZ,VAN,AK,CIP,DO, COT CTX P, AMC, CN, 
151 22 F OG WOUND INFECTION PUS 
MSSA 
   
LZ,VAN,AK,CIP,DO, 
COT, CN,CTX,AMC  P 
152 45 M SKIN CELLULITIS PUS MSSA    LZ,VAN, DO, AK CN,CTX,  P,AMC, COT,CIP 
153 42 F SURGERY ULCER FOOT PUS MSSA    LZ,VAN,AK,CIP,DO, 
, CN,CTX,AMC  P ,COT 
154 2 FCH PAEDIATRICS SEPTICAEMIA BLOOD 
MSSA 
   
LZ,VAN,DO, 
COT, CN,CTX,AMC  P,AK,CIP 
155 5dayS M PAEDIATRICS SEPTICAEMIA BLOOD 
MRSA 
  ECDS LZ,VAN,AK  
P, AMC 
CN,CTX,COT,D
O,CIP 
156 70 M MEDICINE SEPTICAEMIA BLOOD MSSA    LZ,VAN,AK,CIP,DO, COT, CN,CTX,AMC  P 
157 60 M MEDICINE SEPTICAEMIA BLOOD MSSA    LZ,VAN,AK,COT, CN,CTX,AMC  P, DO,CIP, 
158 24 days M NICU 
URINARY 
TRACT 
INFECTION 
URINE MSSA    LZ,VAN,AK,CIP,DO,COT, CN,CTX,AMC  P 
159 77 M MEDICINE 
URINARY 
TRACT 
INFECTION 
URINE MSSA    LZ,VAN,AK, CN,CTX,AMC  P,DO,CIP,COT 
160 24 F OG 
URINARY 
TRACT 
INFECTION 
URINE MSSA    LZ,VAN,AK,CIP,DO, COT, AMC  P, CTX ,CN 
161 5 MCH PAEDIATRICS SEPTICAEMIA BLOOD 
MSSA 
   
LZ,VAN,AK,CIP,DO,CO
T, CN,CTX,AMC  P 
 162 21 F ENT CSOM PUS MSSA    LZ,VAN,AK,CIP,DO,COT, CN,CTX,AMC  P 
163 28 F ENT CSOM WITH DNS PUS 
MSSA 
   
LZ,VAN,AK, DO, 
CN,CTX,AMC  P,CIP,COT 
164 40 M SURGERY CELLULITIS PUS MSSA    LZ,VAN,AK,CIP,DO,COT, CN,CTX,AMC  P, 
165 24 F SURGERY BREAST ABSCESS PUS 
MSSA 
   
LZ,VAN,AK, DO,COT, 
AMC  P, CTX,CN ,CIP 
166 64 M MEDICINE FURUNCLE PUS MSSA    LZ,VAN,AK,CIP,DO,COT, CN,CTX,AMC  P 
167 23 M ENT ASOM PUS MSSA    LZ,VAN,AK,CIP,DO, CN,CTX  P,AMC,COT 
168 30 M SURGERY UTI URINE MSSA    LZ,VAN,AK,CIP,DO,COT, CN,CTX,AMC  P 
169 5 MCH SURGERY WOUND INFECTION 
PUS MSSA 
   
LZ,VAN,AK,CIP,DO,CO
T, CN,CTX,AMC  P 
170 5 MCH SURGERY WOUND INFECTION 
PUS MSSA 
   
LZ,VAN,AK,CIP,DO,CO
T, CN,AMC  P,CTX 
171 30 M ORTHO WOUND INFECTION 
PUS MSSA    LZ,VAN, DO,COT, CN,CTX,AMC  P,AK,CIP 
172 64 M SURGERY CELLULITIS PUS MRSA   E,CD-S LZ,VAN, DO,COT  
P, AMC, CIP,AK 
CN,CTX 
173 65 M ORTHO WOUND INFECTION 
PUS MRSA IR   LZ,VAN,AK  
P,AMC,CIP,  
COT,DO 
,CN,CTX 
174 28 F OG WOUND INFECTION 
PUS MRSA 
  
E,CD-
S LZ,VAN, DO,COT  
P, AMC, AK, CIP 
CN,CTX 
175 23 F OG WOUND INFECTION 
PUS MRSA 
  
E,CD-
S LZ,VAN, AK  
P,  AMC ,CN,  
CTX, 
COT,DO,CIP 
176 35 M ORTHO WOUND INFECTION 
PUS MSSA    LZ,VAN,AK,CIP,DO, COT, CN  P,AMC ,CTX 
177 21 M SURGERY GANGRENE FOOT 
PUS MRSA IR   LZ,VAN, AK  
P,  AMC, 
COT,DO 
CN,CTX, CIP 
 178 23 F ENT CSOM PUS MRSA  CR  LZ,VAN  
P,  AMC ,CN, 
CTX, 
COT,DO,CIP,AK 
179 65 F SURGERY BURNS PUS MSSA    LZ,VAN,AK,CIP,DO, COT, AMC  P,CN,CTX 
180 21 M ORTHO WOUND INFECTION 
PUS MRSA 
  ECD-S LZ,VAN  
P, AMC,COT ,  
DO,CIP,AK  
CN,CTX, 
181 2 FCH SURGERY WOUND INFECTION 
PUS MSSA    LZ,VAN,AK,CIP,DO, COT, CN,CTX,AMC  P 
182 44 M SKIN TROPHIC ULCER 
PUS MRSA 
  
E,CD-
S LZ,VAN  
P,AMC,COT,DO, 
CN, CTX , 
CIP,AK 
183 25 M ORTHO WOUND INFECTION 
PUS MSSA    LZ,VAN,  AK,CIP DO,COT, CN,CTX,AMC  P, 
184 64 M SURGERY CELLULITIS PUS MRSA  CR  LZ,VAN  
P,AMC,COT,DO, 
CIP,AK,  
CN,CTX 
185 63 M SURGERY CELLULITIS PUS MSSA    LZ,VAN,AK,COT, CN,CTX,AMC  P, DO,CIP 
186 44 M SURGERY ABSCESS PUS MRSA   E,CD-S LZ,VAN, CIP  
P, CN, CTX 
COT,DO,AK,AM
C 
187 74 M MEDICINE PNEUMONIA SPUTUM MSSA    
LZ,VAN, ,DO, 
COT, CN, 
CTX,AMC 
 
P,AK 
,CIP 
188 35 F ORTHO WOUND INFECTION 
PUS MSSA    LZ,VAN,AK,CIP,DO, COT, CN,CTX,AMC  P 
189 23 F OG VAGINITIS VAGINAL SWAB MSSA    
LZ,VAN,AK,CIP,DO, 
CN,CTX ,AMC 
COT 
 P, 
190 61 M ENT CSOM PUS MSSA    LZ,VAN,AK,CIP,DO,COT, CN,CTX,AMC  P 
191 51 M MEDICINE VENOUS ULCER,PUO 
PUS MSSA 
   
LZ,VAN,AK,CIP,DO,CO
T, CN,CTX,AMC  P 
192 48 F ENT CSOM PUS MSSA    LZ,VAN,AK,CIP,DO,COT, CN,CTX,AMC  P 
  
193 20 M ORTHO WOUND INFECTION 
PUS MSSA    LZ,VAN,AK,CIP,DO,COT,  CN,CTX,AMC,P 
194 45 M SURGERY ABSCESS PUS MSSA    LZ,VAN,AK,CIP,DO, COT, CN,CTX,AMC  P 
195 40 M SURGERY NECROTISING FASCITIS 
PUS MSSA    LZ,VAN,AK,COT, CN,CTX,AMC  P, DO,CIP 
196 10mo
nths FCH ORTHO 
WOUND 
INFECTION 
PUS MSSA    LZ,VAN,AK,CIP,DO, COT, CN,CTX,AMC  P 
197 12 MCH SURGERY WOUND INFECTION 
PUS MSSA    LZ,VAN,AK,DO CN,CTX,AMC  P,CIP,COT 
198 18 M ORTHO WOUND INFECTION 
PUS MRSA IR   LZ,VAN,CIP  
P,AMC,COT,DO,
AK 
CN,CTX 
199 51 M SURGERY BURNS PUS MRSA   E,CD-S LZ,VAN, DO,COT  
P, AMC , CIP,AK 
CN,CTX 
200 4 MCH ORTHO WOUND INFECTION 
PUS MSSA    LZ,VAN,AK,CIP,DO, COT, CN,CTX,AMC  P 
Comparative study of inducible and constitutive clindamycin 
resistance among methicillin resistant staphylococcus aureus isolates 
ABSTRACT 
 INTRODUCTION: Staphylococcus aureus is the commonly encountered pathogen 
isolated from clinical specimens.Methicillin Resistant Staphylococcus aureus 
(MRSA)causes variety of human infections resulting in high rate of mortality and 
morbidity.Clindamycin, lincosamide antibiotic is a good option for clinicians to treat 
MRSA infections.AIMS AND OBJECTIVES:The aim of the study was to screen for 
MRSA by disc diffusion method with cefoxitin and oxacillin discs and  to determine 
the prevalence of inducible clindamycin resistance and constitutive clindamycin 
resistance  in MRSA and compare them.MATERIALS AND METHODS:200 
staphylococcus aureus were isolated from samples like pus, blood, sputum, vaginal 
swab, urine and body fluids received in microbiology department of Coimbatore 
Medical College Hospital.They were confirmed by microscopy,culture and 
biochemical reaction.Then MRSA were detected by disc diffusion test using Cefoxitin 
(30µg) and Oxacillin(1µg) discs. Clindamycin resistance were detected by performing 
D-test by placing erythromycin 15µg and clindamycin 2µg discs at 15-20mm interdisc  
distance. RESULTS:Majority of staphylococcus aureus were isolated from pus 
samples (87.5%). Staphylococcus aureus was highly sensitive to linezolid (100%) and 
vancomycin (99%) and 100% resistant to penicillin. Cefoxitin disc detected higher 
percentage (26%) of MRSA than oxacillin disc(24%). Analysis of clindamycin 
resistance in 52 (26%) MRSA isolates showed 42.30% of inducible clindamycin 
resistance, 30.76 % of constitutive clindamycin resistance and 26.92% were sensitive 
to both erythromycin and clindamycin. CONCLUSION:Detection of MRSA is very 
important for treating patients and to prevent its spread. MRSA isolates exhibiting 
inducible clindamycin resistance are seemed to be susceptible to clindamycin in vitro 
but resistant invivo resulting in treatment failure. So‘D’test is suggested along with 
routine antibiotic susceptibility testing to detect inducible clindamycin resistance.   
Key words: Inducible clindamycin resistance, constitutive resistance   
